<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=Windows-1254">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 14">
<meta name=Originator content="Microsoft Word 14">
<link rel=File-List href="geriyatri2_dosyalar/filelist.xml">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Microsoft Office Kullanýcýsý</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Bono</o:LastAuthor>
  <o:Revision>5</o:Revision>
  <o:TotalTime>47</o:TotalTime>
  <o:Created>2018-12-30T15:01:00Z</o:Created>
  <o:LastSaved>2019-01-18T17:29:00Z</o:LastSaved>
  <o:Pages>48</o:Pages>
  <o:Words>15495</o:Words>
  <o:Characters>88328</o:Characters>
  <o:Company>UNUN</o:Company>
  <o:Lines>736</o:Lines>
  <o:Paragraphs>207</o:Paragraphs>
  <o:CharactersWithSpaces>103616</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData href="geriyatri2_dosyalar/themedata.thmx">
<link rel=colorSchemeMapping href="geriyatri2_dosyalar/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Print</w:View>
  <w:Zoom>124</w:Zoom>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>TR</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <w:DocumentVariables>
   <w:__Grammarly_42____i>H4sIAAAAAAAEAKtWckksSQxILCpxzi/NK1GyMqwFAAEhoTITAAAA</w:__Grammarly_42____i>
   <w:__Grammarly_42___1>H4sIAAAAAAAEAKtWcslP9kxRslIyNDa0MDczMTUwtTA1NDY1NDJS0lEKTi0uzszPAymwrAUAvOBBxiwAAAA=</w:__Grammarly_42___1>
  </w:DocumentVariables>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
  DefSemiHidden="true" DefQFormat="false" DefPriority="99"
  LatentStyleCount="267">
  <w:LsdException Locked="false" Priority="0" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>
  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" Priority="10" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" Priority="11" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" Priority="22" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="false"
   UnhideWhenUsed="false" Name="Table Grid"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:162;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536859905 -1073732485 9 0 511 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:162;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:162;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610610945 1073750107 16 0 415 0;}
@font-face
	{font-family:MyriadPro-Light;
	mso-font-alt:"Arial Unicode MS";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:auto;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:"\@MyriadPro-Light";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:auto;
	mso-font-signature:1 134676480 16 0 131072 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Baþlýk 1 Char";
	mso-style-next:Normal;
	margin-top:24.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:14.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#365F91;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:0pt;
	font-weight:bold;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Açýklama Metni Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Üstbilgi Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Altbilgi Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-noshow:yes;
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Konu Baþlýðý Char";
	mso-style-next:Normal;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:15.0pt;
	margin-left:0cm;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-bottom-alt:solid #4F81BD 1.0pt;
	mso-border-bottom-themecolor:accent1;
	padding:0cm;
	mso-padding-alt:0cm 0cm 4.0pt 0cm;
	font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-noshow:yes;
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Konu Baþlýðý Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-bottom-alt:solid #4F81BD 1.0pt;
	mso-border-bottom-themecolor:accent1;
	padding:0cm;
	mso-padding-alt:0cm 0cm 4.0pt 0cm;
	font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-noshow:yes;
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Konu Baþlýðý Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-bottom-alt:solid #4F81BD 1.0pt;
	mso-border-bottom-themecolor:accent1;
	padding:0cm;
	mso-padding-alt:0cm 0cm 4.0pt 0cm;
	font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-noshow:yes;
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Konu Baþlýðý Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:15.0pt;
	margin-left:0cm;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-bottom-alt:solid #4F81BD 1.0pt;
	mso-border-bottom-themecolor:accent1;
	padding:0cm;
	mso-padding-alt:0cm 0cm 4.0pt 0cm;
	font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;}
a:link, span.MsoHyperlink
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:purple;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
pre
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"HTML Önceden Biçimlendirilmiþ Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"Açýklama Metni";
	mso-style-link:"Açýklama Konusu Char";
	mso-style-next:"Açýklama Metni";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Balon Metni Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-fareast-language:EN-US;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{mso-style-noshow:yes;
	mso-style-priority:1;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.MsoSubtleEmphasis
	{mso-style-priority:19;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	color:gray;
	mso-themecolor:text1;
	mso-themetint:127;
	font-style:italic;}
span.Balk1Char
	{mso-style-name:"Baþlýk 1 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Baþlýk 1";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#365F91;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-fareast-language:TR;
	font-weight:bold;}
span.HTMLncedenBiimlendirilmiChar
	{mso-style-name:"HTML Önceden Biçimlendirilmiþ Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"HTML Önceden Biçimlendirilmiþ";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";
	mso-fareast-language:TR;}
span.AklamaMetniChar
	{mso-style-name:"Açýklama Metni Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Açýklama Metni";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
span.stbilgiChar
	{mso-style-name:"Üstbilgi Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Üstbilgi;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
span.AltbilgiChar
	{mso-style-name:"Altbilgi Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Altbilgi;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
span.KonuBalChar
	{mso-style-name:"Konu Baþlýðý Char";
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Konu Baþlýðý";
	mso-ansi-font-size:26.0pt;
	mso-bidi-font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;
	mso-fareast-language:TR;}
span.AklamaKonusuChar
	{mso-style-name:"Açýklama Konusu Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"Açýklama Metni Char";
	mso-style-link:"Açýklama Konusu";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;
	font-weight:bold;}
span.BalonMetniChar
	{mso-style-name:"Balon Metni Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Balon Metni";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.msonormal0, li.msonormal0, div.msonormal0
	{mso-style-name:msonormal;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.headinganchor, li.headinganchor, div.headinganchor
	{mso-style-name:headinganchor;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.bulletindent1, li.bulletindent1, div.bulletindent1
	{mso-style-name:bulletindent1;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	color:black;
	mso-fareast-language:EN-US;}
span.stBilgiChar0
	{mso-style-name:"Üst Bilgi Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Üst Bilgi";
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
p.stBilgi, li.stBilgi, div.stBilgi
	{mso-style-name:"Üst Bilgi";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-link:"Üst Bilgi Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.AltBilgiChar0
	{mso-style-name:"Alt Bilgi Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Alt Bilgi";
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
p.AltBilgi, li.AltBilgi, div.AltBilgi
	{mso-style-name:"Alt Bilgi";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-link:"Alt Bilgi Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.glyph
	{mso-style-name:glyph;
	mso-style-unhide:no;}
span.h1
	{mso-style-name:h1;
	mso-style-unhide:no;}
span.headingendmark
	{mso-style-name:headingendmark;
	mso-style-unhide:no;}
span.nowrap
	{mso-style-name:nowrap;
	mso-style-unhide:no;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;
	mso-style-unhide:no;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-size:10.0pt;
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
@page WordSection1
	{size:612.0pt 792.0pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:155583761;
	mso-list-type:hybrid;
	mso-list-template-ids:786570436 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:38.45pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:74.45pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:110.45pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:146.45pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:182.45pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:218.45pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:254.45pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:290.45pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:326.45pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1
	{mso-list-id:213203066;
	mso-list-type:hybrid;
	mso-list-template-ids:-1184039740 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2
	{mso-list-id:290791737;
	mso-list-type:hybrid;
	mso-list-template-ids:-363569078 1593456880 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:14.0pt;
	font-family:Symbol;}
@list l2:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3
	{mso-list-id:426654361;
	mso-list-type:hybrid;
	mso-list-template-ids:-1535328612 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l3:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4
	{mso-list-id:835070106;
	mso-list-type:hybrid;
	mso-list-template-ids:-1822249982 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l4:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l4:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l4:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l5
	{mso-list-id:882134769;
	mso-list-type:hybrid;
	mso-list-template-ids:1663064120 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l5:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l5:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l5:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l5:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l5:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l5:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l5:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l5:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l6
	{mso-list-id:898243831;
	mso-list-type:hybrid;
	mso-list-template-ids:-1483986816 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l6:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l6:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l6:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l6:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l6:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l6:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l6:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l6:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l7
	{mso-list-id:1084113065;
	mso-list-type:hybrid;
	mso-list-template-ids:-1054206956 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l7:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l7:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l7:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l7:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l7:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l7:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l7:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l7:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l8
	{mso-list-id:1096711148;
	mso-list-type:hybrid;
	mso-list-template-ids:876135142 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l8:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l8:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l8:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l8:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l8:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l8:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l8:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l8:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l8:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l9
	{mso-list-id:1218130015;
	mso-list-type:hybrid;
	mso-list-template-ids:-633699172 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l9:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l9:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l9:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l9:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l9:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l9:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l9:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l9:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l10
	{mso-list-id:1221287162;
	mso-list-type:hybrid;
	mso-list-template-ids:-630536060 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l10:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l10:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l10:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l10:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l10:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l10:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l10:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l10:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l10:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l11
	{mso-list-id:1240866410;
	mso-list-type:hybrid;
	mso-list-template-ids:-603551838 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l11:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l11:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l11:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l11:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l11:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l11:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l12
	{mso-list-id:1260723200;
	mso-list-type:hybrid;
	mso-list-template-ids:-1059832774 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l12:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:53.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:89.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l12:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:125.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l12:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:161.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:197.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l12:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:233.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l12:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:269.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:305.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l12:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:341.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l13
	{mso-list-id:1424692309;
	mso-list-type:hybrid;
	mso-list-template-ids:1648648058 1028531424 837055474 -1526458792 1927164286 640699860 438439470 1682710464 1605390978 -988150456;}
@list l13:level1
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level2
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level3
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level4
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level5
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level6
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level7
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level8
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level9
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l14
	{mso-list-id:1575505450;
	mso-list-type:hybrid;
	mso-list-template-ids:1864788114 1111110392 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l14:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l14:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l14:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l14:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l14:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l14:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l14:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l14:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l14:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l15
	{mso-list-id:1590115035;
	mso-list-type:hybrid;
	mso-list-template-ids:-1660671460 -329737276 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l15:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:12.0pt;
	font-family:Symbol;}
@list l15:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l15:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l15:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l15:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l15:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l15:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l15:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l15:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l16
	{mso-list-id:1595629179;
	mso-list-type:hybrid;
	mso-list-template-ids:-1738529938 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l16:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l16:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l16:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l16:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l16:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l16:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l16:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l16:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l16:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l17
	{mso-list-id:1629625867;
	mso-list-type:hybrid;
	mso-list-template-ids:-1557993258 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l17:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l17:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l17:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l17:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l17:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l17:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l17:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l17:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l17:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l18
	{mso-list-id:1765370467;
	mso-list-type:hybrid;
	mso-list-template-ids:1757575586 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l18:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l18:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l18:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l18:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l18:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l18:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l18:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l18:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l18:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l19
	{mso-list-id:1814785034;
	mso-list-type:hybrid;
	mso-list-template-ids:187487254 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l19:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l19:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l19:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l19:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l19:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l19:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l19:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l19:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l19:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l20
	{mso-list-id:1826506151;
	mso-list-type:hybrid;
	mso-list-template-ids:-677095888 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l20:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l20:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l20:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l20:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l20:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l20:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l20:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l20:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l20:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l21
	{mso-list-id:1851405966;
	mso-list-type:hybrid;
	mso-list-template-ids:1771352722 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l21:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l21:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l21:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l21:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l21:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l21:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l21:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l21:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l21:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l22
	{mso-list-id:2020303116;
	mso-list-type:hybrid;
	mso-list-template-ids:-1534320572 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l22:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:71.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l22:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:107.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l22:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:143.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l22:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:179.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l22:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:215.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l22:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:251.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l22:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:287.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l22:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:323.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l22:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:359.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
table.MsoTableGrid
	{mso-style-name:"Tablo Kýlavuzu";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:39;
	mso-style-unhide:no;
	border:solid windowtext 1.0pt;
	mso-border-alt:solid windowtext .5pt;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid windowtext;
	mso-border-insidev:.5pt solid windowtext;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
table.TabloKlavuzuAk1
	{mso-style-name:"Tablo Kýlavuzu Açýk1";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-priority:40;
	mso-style-unhide:no;
	border:solid #BFBFBF 1.0pt;
	mso-border-themecolor:background1;
	mso-border-themeshade:191;
	mso-border-alt:solid #BFBFBF .5pt;
	mso-border-themecolor:background1;
	mso-border-themeshade:191;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid #BFBFBF;
	mso-border-insideh-themecolor:background1;
	mso-border-insideh-themeshade:191;
	mso-border-insidev:.5pt solid #BFBFBF;
	mso-border-insidev-themecolor:background1;
	mso-border-insidev-themeshade:191;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
table.DzTablo11
	{mso-style-name:"Düz Tablo 11";
	mso-tstyle-rowband-size:1;
	mso-tstyle-colband-size:1;
	mso-style-priority:41;
	mso-style-unhide:no;
	border:solid #BFBFBF 1.0pt;
	mso-border-themecolor:background1;
	mso-border-themeshade:191;
	mso-border-alt:solid #BFBFBF .5pt;
	mso-border-themecolor:background1;
	mso-border-themeshade:191;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid #BFBFBF;
	mso-border-insideh-themecolor:background1;
	mso-border-insideh-themeshade:191;
	mso-border-insidev:.5pt solid #BFBFBF;
	mso-border-insidev-themecolor:background1;
	mso-border-insidev-themeshade:191;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
table.DzTablo11FirstRow
	{mso-style-name:"Düz Tablo 11";
	mso-table-condition:first-row;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.DzTablo11LastRow
	{mso-style-name:"Düz Tablo 11";
	mso-table-condition:last-row;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-tstyle-border-top:1.5pt double #BFBFBF;
	mso-tstyle-border-top-themecolor:background1;
	mso-tstyle-border-top-themeshade:191;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.DzTablo11FirstCol
	{mso-style-name:"Düz Tablo 11";
	mso-table-condition:first-column;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.DzTablo11LastCol
	{mso-style-name:"Düz Tablo 11";
	mso-table-condition:last-column;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.DzTablo11OddColumn
	{mso-style-name:"Düz Tablo 11";
	mso-table-condition:odd-column;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-tstyle-shading:#F2F2F2;
	mso-tstyle-shading-themecolor:background1;
	mso-tstyle-shading-themeshade:242;}
table.DzTablo11OddRow
	{mso-style-name:"Düz Tablo 11";
	mso-table-condition:odd-row;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-tstyle-shading:#F2F2F2;
	mso-tstyle-shading-themecolor:background1;
	mso-tstyle-shading-themeshade:242;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=TR link=blue vlink=purple style='tab-interval:35.4pt'>

<div class=WordSection1>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .5pt;
padding:0cm;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-size:16.0pt;mso-bidi-font-size:12.0pt;font-family:
"Tahoma","sans-serif"'>YAÞL<span style='mso-no-proof:yes'>I</span> NÖROLOJÝK
HASTAYA YAKLAÞIM <o:p></o:p></span></b></p>

<p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .5pt;
padding:0cm;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:"Tahoma","sans-serif"'>Yazanlar: Gülistan
Bahat, Tuðba Erdoðan, Mehmet Akif Karan <o:p></o:p></span></b></p>

<p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .5pt;
padding:0cm;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:"Tahoma","sans-serif"'>Son güncelleþtirme
tarihi: 22.12.2018<o:p></o:p></span></b></p>

</div>

<p class=MsoNormal><span style='font-size:16.0pt;mso-bidi-font-size:12.0pt;
font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-bidi-font-style:italic'>Yaþlýlýk pek çok saðlýk probleminin bir
araya gelebildiði kaçýnýlmaz bir süreçtir. Bu sürecin herhangi bir döneminde,
doktorlar ve diðer saðlýk çalýþanlarý mutlaka yaþlý hastayla karþýlaþýr.</span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
Bazý nörolojik hastalýklarýn görülme sýklýðý yaþlanma ile birlikte belirgin
artýþ gösterir. Bu hastalýklarýn baþýnda inme ve nörodejeneratif hastalýklar
gelmektedir. Yaþ, Alzheimer hastalýðý (AH) için en önemli risk faktörüdür ve
hastalýðýn prevalansý 65 yaþýndan sonra her 5 yýlda bir katlanarak artmaktadýr.
Parkinson hastalýðýnýn (PH) prevalansý yaþla birlikte artmaktadýr. Progresif
supranükleer felç (PSP), Lewy cisimcikli demans (LCD), frontotemporal demans
(FTD), amiyotrofik lateral skleroz (ALS) gibi birçok nörodejeneratif hastalýðýn
prevalansýnýn yaþla birlikte arttýðý bilinmektedir. Ýnme geçirenlerin %70i 65
yaþýn üzerindedir. Epilepsi insidansýnýn yüksek olduðu iki dönem yaþamýn ilk
yýlý ve 60 yaþ sonrasýdýr. Yaþlýlarda metastatik beyin tümörleri,
serebrovasküler hastalýklar (SVH) ve dejeneratif beyin hastalýklarýnýn daha sýk
görülmesi epilepsi insidansýnýn da artmasýna katkýda bulunur. Nörolojik
hastalýklarýn önemli bir kýsmýnýn yaþlýlarda görülmesi nedeniyle, bu hastalarý
deðerlendirme aþamasýnda yaþlý hastanýn deðerlendirilmesindeki farklýlýklarýn
bilinmesi günlük pratikte önem taþýr. Yaþlýnýn karmaþýk ve birbirini etkileyen
sorunlarý nedeniyle ayrýntýlý bir geriatrik deðerlendirme yoðun bir
interdisipliner süreç olup çok miktarda verinin elde edilmesi ile
sonuçlanacaktýr. Geriatrik deðerlendirme ile mevcut hastalýklar ortaya
çýkarýlabilir, ilaçlar ve tedaviler ile iliþkili yan etkiler, hastaneye baþvuru
ve hastanede yatýþ süresi, bakýmevlerinde kalýþ ihtiyacý ve saðlýk ve bakým
maliyetleri azaltýlabilir.<span style='mso-spacerun:yes'>  </span>Yaþlý
bireylerin büyük bir kýsmý geriatrik deðerlendirmeden anlamlý fayda görür.
Bununla birlikte kapsamlý geriatrik deðerlendirmeden; eþlik eden komorbidite ve
kullanýlan ilaç sayýsý düþük olan saðlýklý yaþlýlardan ziyade, kýrýlgan
veya kuruma yerleþtirilme riski yüksek, fonksiyonel durumunda gerileme olan
veya olma riski taþýyan yaþlýlar en yüksek faydayý görecektir. Bu nedenle
özellikle bu hasta grubunda kapsamlý geriatrik deðerlendirme yapýlmalýdýr. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Yaþlanma
ile bazý nörolojik hastalýklardaki artýþýn yaný sýra toplumda en sýk görülen
kronik hastalýklar olan hipertansiyon ve diabetes mellitus gibi <span
class=GramE>dahili</span> hastalýklarýn prevalansý artar. Buna paralel olarak
kullanýlan ilaç sayýsý, düþmeler, inkontinans, malnütrisyon, sarkopeni,
konstipasyon, deliryum vb. gibi geriatrik tablolarýn prevalansý da artar. Bu
durum yaþlý hastanýn klinik yönetimini daha karmaþýk hale getirir. Kapsamlý
geriatrik deðerlendirme ile yaþlý hastanýn klinik yönetimden en fazla fayda ve
en az zarar görmesinin saðlanmasý amaçlanýr. Nörolojik hastalýðý olan
yaþlýlarda bu hastalýðýn klinik kötüleþmesine katkýda bulunabilecek
düzeltilebilir birçok <span class=GramE>dahili</span> faktör mevcuttur. Yaþlý
hastalarda sýk karþýlaþýlan ve yukarda sayýlan geriatrik tablolar iþlevsellikte
bozulmaya ve mevcut nörolojik hastalýðýn kötüleþmesine katkýda bulunabilir.
Ayrýca bu hastalarda nörolojik hastalýðýn tedavisinde kullanýlan ilaçlarýn
sebep olabileceði <span class=GramE>dahili</span> yan etkiler ve ilaç-ilaç
etkileþimleri de söz konusudur. Öte yandan <span class=GramE>dahiliyede</span>
sýk kullanýlan ilaçlarýn bazýlarý mevcut nörolojik hastalýðýn klinik
kötüleþmesine neden olabilmektedir. Nörolojik hastalýðý olan yaþlýlarda
diyabet, hipertansiyon, hiperlipidemi ve hipo-hipertiroidi gibi sistemik hastalýklarla
sýklýkla karþýlaþýlmaktadýr; bu baþlýklarýn her birine özel yaklaþým gözden
geçirilecektir.<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";text-transform:uppercase'>Nörolojik
hastalýðýn klinik kötüleþmesine katkýda bulunabilecek düzeltilebilir <span
class=GramE>DAHÝLÝ</span> faktörlerin tanýnmasý ve tedavisi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Nörolojik
hastalýðý olan yaþlýda klinik kötüleþme 4 farklý þekilde ortaya çýkabilir.<span
style='mso-spacerun:yes'>  </span>Özgün nörolojik hastalýðýn belirtilerinde
kötüleþme, kognitif bozulma, davranýþsal bozulma ve/veya iþlevsel bozulma.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Bir
yaþlýda normal nöronal iþlevlerin sürdürülebilmesi için yeterli makro ve mikro
besinlerin alýnmasý, yeterli oksijenizasyonun saðlanmasý, uygun hormonal
durumun olmasý, dengeli elektrolit ve pHa sahip olunmasý ve toksik olmayan
ortamda bulunulmasý gereklidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>Normal nöronal iþlevi bozabilecek birçok sistemik
veya metabolik bozukluk mevcuttur. Yaþlýda hiperglisemi, hipoglisemi, hipoksi,
hiperkarbi, hipotansiyon, hipertansiyon, dehidratasyon, elektrolit
dengesizlikleri, asidoz, alkoloz, böbrek yetersizliði, karaciðer yetersizliði,
maliniteler, sistemik infeksiyonlar, anemi, nütrisyonel eksiklikler,
hipotiroidi, hipertiroidi, toksik ajanlar ve ilaç yan etkileri gibi birçok
faktör tek baþýna veya beraber nöronal iþlevlerde bozukluða neden olabilir.
Yaþlýlarýn komorbid hastalýklarýnýn çokluðu nedeniyle bu mevcut bozukluklarla
karþýlaþma oraný oldukça yüksektir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:408.4pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><span style='mso-tab-count:1'>                                                                                                             </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>Nöronal iþlev bozukluðu gerçekleþen hastada ilk
yapýlmasý gereken adým ayrýntýlý anamnez alýnmasýdýr. Yaþlýda geliþen yeni <span
class=GramE>semptom</span> ve bulgularýn yaklaþýk 1/3ünden ilaçlarýn sorumlu
olduðu bilinmekte, bu nedenle özellikle aldýðý ilaçlarýn yan etki profili,
ilaç-ilaç etkileþimleri ve endikasyonlarý açýsýndan gözden geçirilmesi çok
önemlidir. Anamnez sonrasý <span class=GramE>dahili</span> fizik muayeneden
sonra laboratuvar deðerlendirilmesi yapýlmalýdýr.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>Birinci basamakta istenecek laboratuvar tetkikleri;
akut faz reaktanlarýnýn düzeyleri, kan þekeri, böbrek fonksiyon testleri,
karaciðer fonksiyon testleri, elektrolitler, kalsiyum, tam kan sayýmý, O<sup>2</sup>-CO<sup>2</sup>
düzeyi, pH, EKG, tiroid fonksiyon testleri ve B12 vitamin düzeyidir. Hastanýn
kliniðine göre istenebilecek ileri tetkikler arasýnda kortizol düzeyi, amonyak
düzeyi, ileri görüntülemeler ve EEG sayýlabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Deliryum <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>Deliryum; yaþlý hastalarda sýk karþýlaþýlan, <span
class=GramE>dahili</span> problemlerin sebep olabileceði kognitif bozukluklar
arasýnda olup önlenebilir olmasý nedeniyle geriatri pratiðinde özellikle önemli
bir yere sahiptir. </span><span style='font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>Kognitif fonksiyonlarda, dikkatte ve duygudurumda
akut baþlangýçlý, gün içinde dalgalanmalarla seyreden bozukluðu ifade
etmektedir. Hastane dýþýnda yaþayan yaþlýlarda deliryum sýklýðý %1 ile %2
arasýnda iken hastanelere kabul sýrasýnda deliryum %10 ile %40 arasýnda bir
sýklýkta görülmektedir. Operasyon geçiren ve özellikle kalça kýrýðý olan
yaþlýlarda deliryum görülme sýklýðý %15-%53 arasýndadýr.</span><span
style='font-family:"Tahoma","sans-serif";color:black'> </span><span
style='font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Yoðun
bakým ünitelerinde yatan yaþlý hastalarda ise bu oranlar %70 ile %87ye kadar
çýkmaktadýr. </span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-bidi-font-weight:bold'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Deliryum için taný <span class=GramE>kriterleri</span>
mevcut olmasýna ve taný konduðunda komplikasyonlarýnýn önlenebilir olmasýna
raðmen, sýklýkla gözden kaçabilmekte, hastalarýn %30-60ý taný almamaktadýr. </span><span
style='font-family:"Tahoma","sans-serif"'>Deliryum geliþen hastalarda hastane
yatýþ su&#776;resi uzamakta, fonksiyonel kapasite azalmakta, maliyet
artmaktadýr. Ayrýca deliryum, kalýcý kognitif bozukluk, basý yaralarý, du&#776;þme,
pnömoni, mortalite artýþý (%10-65) ve bakýmevine yerleþtirilmeye neden olabilmektedir.
<span style='color:black;mso-themecolor:text1;mso-bidi-font-weight:bold'>Deliryum,
hastalarda deliryumu kolaylaþtýrýcý faktörler (predispozan) ile deliryumu
tetikleyici faktörlerin (presipite edici) etkileþmesi ile oluþmaktadýr.
Predispozan faktörler arasýnda en sýk karþýlaþýlan durum demans varlýðýdýr.
Demansý olan yaþlý hastalarda deliryum sýklýðý 2 ila 5 kat daha fazla
görülebilmektedir. </span></span><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:black;mso-themecolor:
text1;mso-bidi-font-weight:bold'>En sýk karþýlaþýlan deliryumu tetikleyici
faktör ise ilaçlardýr. </span><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Ýlaçlarýn deliryumda önemli
bir rolu&#776; vardýr. Ýlacýn tu&#776;ru&#776;nden baðýmsýz olarak 4 ve u&#776;zerinde
ilaç kullanmak (polifarmasi) deliryum için bir risk faktöru&#776;yken, 24 saat
içinde u&#776;ç taneden fazla ilaç baþlanmasý da deliryumu presipite edebilir. <span
style='color:#212121'>Son çalýþmalarda ilaçlarýn deliryum vakalarýnýn %22 ile
%39'una katkýda bulunduðu saptanmýþtýr. Her hastada reçetesiz ilaçlar da <span
class=GramE>dahil</span> olmak üzere mevcut ilaçlarýn listesi gözden
geçirilmelidir. Deliryum riski olan bir hastada altta yatan predispozan ve
presipite eden faktörlerin (<b style='mso-bidi-font-weight:normal'>Tablo 1</b>)
sorgulanmasý ve düzeltilebilecek faktörlerin ortadan kaldýrýlmasý ile deliryum
geliþim riskini azaltmak mümkündür. <o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Yaþlý hastalarda deliryumda dikkat
edilmesi gereken diðer bir nokta infeksiyonlardýr. Yaþlý hastada infeksiyonun
diðer bulgularý ortaya çýkmadan ilk belirti deliryum olabilir. Bu nedenle
deliryum tablosu ile baþvuran her yaþlý hastada muhtemel bir infeksiyon odaðý
açýsýndan mutlaka gerekli deðerlendirmeler yapýlmalýdýr.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;color:black;mso-themecolor:
text1;mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Tablo 1. </span></b><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Deliryumda predizpozan ve presipite edici faktörler</span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1;mso-bidi-font-weight:bold'><o:p></o:p></span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=318 valign=top style='width:238.65pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:150%'><b><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US'>Deliryumda
  predizpozan faktörler<o:p></o:p></span></b></p>
  </td>
  <td width=318 valign=top style='width:238.65pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:150%'><b
  style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Deliryumu
  presipite eden faktörler<o:p></o:p></span></b></p>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><b><u><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US'><o:p><span
   style='text-decoration:none'>&nbsp;</span></o:p></span></u></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
  <td width=318 valign=top style='width:238.65pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Ýleri
  yaþ (65 yaþ ve üzeri)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kýrýlgan
  yaþlý<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Polifarmasi<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kardiyopulmoner
  hastalýklar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Organ
  yetmezlikleri (böbrek, karaciðer)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Santral
  sinir sistemi hastalýklarý<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kognitif
  bozukluk, demans<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Parkinson
  hastalýðý<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Depresyon<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Görme-iþitme
  sorunlarý<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Malnütrisyon<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kontrol
  altýnda olmayan birden fazla týbbi sorun<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Sosyal
  <span class=GramE>izolasyon</span><o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l15 level1 lfo4'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:black;
  mso-themecolor:text1;mso-fareast-language:EN-US;mso-bidi-font-weight:bold'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Fonksiyonel
  yetersizlik<span style='color:black;mso-themecolor:text1;mso-bidi-font-weight:
  bold'><o:p></o:p></span></span></p>
  </td>
  <td width=318 valign=top style='width:238.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l8 level1 lfo6'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Ýlaçlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Antikolinerjikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Trisiklik
  antidepresanlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Steroidler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Benzodiazepinler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Antihistaminikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Antibiyotikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Digoksin<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Aðrý
  kesiciler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Ýnfeksiyonlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Ateþ,
  hipotermi, hipoksi, hiperkarbi, elektrolit bozukluklarý<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kardiyovasküler
  hastalýklar (akut miyokard infarktüsü, kalp yetersizliði, hipotansiyon)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Hastaneye
  yatmak, yoðun bakým ünitesine yatmak, invazif giriþimler, cerrahi giriþimler
  (özellikle ortopedik)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Aðrý<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Konstipasyon,
  fekal impakt<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Üriner
  retansiyon<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Fiziksel
  kýsýtlamalar (idrar yolu sondasý takýlmasý gibi)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Ýmmobilizasyon<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Uyku
  uyanýklýk siklusunun bozulmasý<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kafa
  <span class=GramE>travmasý</span>, yanýk<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;mso-fareast-language:
  EN-US;mso-bidi-font-weight:bold'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Çevresel
  faktörler<b><u><span style='color:black;mso-themecolor:text1'><o:p></o:p></span></u></b></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:150%'><sup><span
style='mso-bidi-font-size:10.0pt;line-height:150%;color:red;mso-bidi-font-weight:
bold'><o:p>&nbsp;</o:p></span></sup></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Deliryumda
Tanýsal Yaklaþým<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Deliryum tanýsýnda en önemli nokta
detaylý anamnez, fizik, nörolojik ve mental durum muayeneleri ile hastanýn
mevcut bazal durumunda bir deðiþiklik olup olmadýðýnýn anlaþýlmasýdýr. En sýk
kullanýlan taný <span class=GramE>kriteri</span> Amerikan Psikiyatri Derneðinin
yayýnladýðý The Diagnostic and Statistical Manual of Mental Disorders (DSM)
kriteridir. DSM-5 kriterlerine göre dikkati bir konu üzerinde odaklama,
sürdürme ya da yeni bir konuya kaydýrma yetisinde azalma ile giden bilinç
bozukluðu olmasý, çevrede olup bitenin farkýnda olma düzeyinde azalma olmasý ve
bu durumun kýsa bir süre içerisinde geliþmesi, dalgalanma eðilimi göstermesi;
bellek kaybý, <span class=GramE>oryantasyon</span> bozukluðu, dil
fonksiyonlarý, görsel-mekansal iþlevler ve algý gibi kognitif fonksiyonlarda
bozukluk olmasý gerekmektedir. Kriterlere göre bu durum daha önceden var olan
bir nörokognitif bozuklukla açýklanamýyor olmalý ve koma gibi ileri derecede
azalmýþ uyanýklýk düzeyi baðlamýnda ortaya çýkmamalýdýr. Anamnez, fizik muayene
ve laboratuvar bulgularýndan elde edilen verilerde bu bozukluðun genel týbbi
durumun doðrudan etkilerine baðlý olduðuna iliþkin kanýtlar olmalýdýr.<span
style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Deliryum taramasýnda kullanýlan
ölçekler arasýnda Mini Mental Durum Deðerlendirme Testi (MMSE), Konfu&#776;zyon
Deðerlendirme Metodu (CAM) yer almaktadýr. CAM %94-100 duyarlýlýk ve %90-95
özgüllüðe sahiptir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Yaþlý hastalarda deliryum
deðerlendirilmesinde ana basamaklar þunlardýr:<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>1. Kognitif durumun, mental durum ve
dikkatin test edilmesi ve bazal kognitif durumun saptanmasý.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>2. Kapsamlý <span class=GramE>hikaye</span>
ve fizik muayene, nörolojik muayene yapýlmasý.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>3. Ýlaç listesinin gözden geçirilmesi:
Tu&#776;m ilaçlarýn yan etkilerinin gözden geçirilmesi. Tu&#776;m psikoaktif
ilaçlarýn kesilmesi veya azaltýlmasý.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>4. Laboratuvar deðerlendirme: tam kan
sayýmý, elektrolitler, BUN, kreatinin, glukoz, kalsiyum, fosfor, karaciðer
enzimleri, oksijen satürasyonu, tiroid fonksiyon testleri.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>5. Ýnfeksiyon aranmasý: fizik muayene,
idrar tetkiki, akciðer grafisi, ku&#776;ltu&#776;rler (endikasyon varsa).<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>6. Yukarýdaki basamaklarda iliþkili
sebep bulunamazsa seçilmiþ hastalarda ileri deðerlendirme yapýlmasý. Ýleri
laboratuvar testleri; arteryel kan gazý, EKG, kalp enzimleri, beyin
görüntülemesi, beyin omurilik sývýsý incelemesi, elektroensefalogram.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ýnfeksiyonlar
<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Kötü
<span class=GramE>hijyen</span> ve malnütrisyon nedeniyle yaþlý nörolojik
hastalar her türlü infeksiyon hastalýðýna açýktýrlar. Terminal dönem hastalarda
aspirasyon pnömonisi sýklýkla karþýlaþýlan bir problemdir. Yaþlýlarda
infeksiyon hastalýklarýnýn tipik semptom ve bulgularý (ateþ, dispne, <span
class=GramE>lökositoz ...</span> vb) olmayabilir. Kognitif fonksiyonda ve
iþlevsellikte akut kötüleþme durumunda infeksiyonlar mutlaka akla gelmelidir.
Uygun ve yeterli süre antibiyoterapi uygulanmalýdýr. Yaþlanma ile birlikte
immün fonksiyonlarda deðiþiklik olur (immünosenesans). Yaþamýn immünolojik
olarak hassas dönemlerinden olan çocukluk çaðýnda olduðu gibi ileri yaþta da
infeksiyon hastalýklarýndan korunma amacýyla bazý özgün aþýlarýn kullanýlmasý
ile yaþlýlarda önemli bir morbidite ve mortalite sebebi olan infeksiyon
hastalýklarýnýn azaltýlmasý saðlanabilir. Yaþlýlarda rutin olarak uygulanmasý
önerilen aþýlar aþaðýda özetlenmiþtir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Korunma
<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Pnömokok
Aþýsý: Daha önce pnömokok aþýsý yapýlmamýþ 65 yaþ ve üzeri bireylerde ilk doz
13 valan konjuge aþý, takiben en az 1 yýl sonra 23 valan polisakkarid aþý
þeklinde uygulanmalýdýr. Önceden 23 valan polisakkarid aþý ile aþýlanmýþsa 1
yýl sonra konjuge aþý yapýlmalýdýr. 23 valan aþý 65 yaþ öncesinde uygulanmýþsa,
65 yaþ üstünde ilk aþýdan en az 5 yýl sonra tekrarlanmalýdýr <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Ýnfluenza
Aþýsý: 50 yaþ üstü tüm eriþkinlere yýllýk mevsimsel grip aþýsý önerilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Tetanoz
Aþýsý: Her 10 yýlda bir eriþkin tipi difteri-tetanoz toksoidi önerilir. Erken
eriþkinlik dönemi veya çocuklukta aþýlananlar için ara açýlabilir. Bu olgularda
50 yaþ üstü yapýlan tek bir td toksoidi ömür boyu immünite için yeterli
olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Herpes
Zoster Aþýsý: Zoster infeksiyonu riski yaþ ilerledikçe artmaktadýr Zoster
infeksiyonu iliþkili postherpetik nevralji, ensefalit, miyelit, kranyal ve
periferik sinir paralizileri yaþlýlarda daha fazladýr. Herpes zoster aþýsý zona
riskinde ve postherpetik nevralji riskinde azalma saðlar. Atmýþ yaþ üstü immün
sorunu olmayan tüm yaþlýlara ömür boyu bir kez olmak üzere önerilebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><u><span
style='mso-bidi-font-size:14.0pt;line-height:150%;background:white'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
text-transform:uppercase'>Nörolojik hastalýklarda iþlevsellikte bozulmaya
katkýda bulunabilecek geriatrik sendromlar<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Yaþlanma
ile birlikte malnütrisyon, sarkopeni, düþme, inkontinans, konstipasyon gibi
sorunlarýn sýklýðý artar. Standart nörolojik ve <span class=GramE>dahili</span>
deðerlendirmede bunlar gözden kaçar. Yukarýda sayýlan durumlar yaþlý hastalarda
sýk olarak görülen, yaþam kalitesini bozup, morbidite ve mortaliteyi
arttýrabilen geriatrik <span class=GramE>sendrom</span> olarak nitelendirilen
durumlardýr. <span style='color:black;mso-themecolor:text1'>Yaþlýda çoðunlukla
atipik <span class=GramE>semptomlarla</span> kendini gösteren ve hastalýk
tanýmý</span></span><span style='font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1'> ile tam olarak açýklanamayan klinik durumlarý ve
semptomlarý tanýmlamak için Geriatrik Sendromlar terimi
kullanýlmaktadýr.&nbsp;</span><span style='font-family:"Tahoma","sans-serif"'> </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Nörolojik
hastalýðý olan yaþlýlarda geriatrik <span class=GramE>sendromlarýn</span>
varlýðý iþlevselliði bozacaktýr.<span style='mso-spacerun:yes'>  </span>Bu
nedenle sýk karþýlaþýlan geriatrik <span class=GramE>sendromlarýn</span>
varlýðýnýn sorgulanmasý ve gerekli önlemlerin alýnmasý önem arz etmektedir. Bu
geriatrik <span class=GramE>sendromlarýn</span> tanýsý, tedavisi aþaðýda kýsaca
özetlenecektir. </span><span style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal><span style='mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Malnütrisyon<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:black'>Malnu&#776;trisyona sebep
olduðu bilinen nörolojik hastalýklar arasýnda Alzheimer hastalýðý, Parkinson
hastalýðý, serebrovasküler hastalýk, multipl skleroz ve motor nöron hastalýðý
bulunur. Nörolojik hastalýklarýn seyrinde geliþen malnu&#776;trisyonun
nedenleri arasýnda depresyon, öz bakýmýn bozulmasý, orofarengial disfaji,
bilinç bozukluklarý, algýlamada güçlük, kognitif bozukluk, ilaçlar ve artmýþ
ihtiyaç sayýlabilir. Malnütrisyon sonucunda, kas atrofisi (ekstremite/solunum),
basý yaralarý, du&#776;þmeler, osteoporoz, infeksiyon riski ve saðkalýmda
azalma göru&#776;lu&#776;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Malnütrisyon bir ya da daha fazla besin
maddesinin vücut dengesini bozacak þekilde yetersiz alýnmasýdýr. Metabolik
ihtiyaçlarý karþýlayacak kadar enerji ve/veya proteinin olmamasý malnütrisyonun
temel özelliðidir. Yaþlýlarýn %37-40ý gu&#776;nlu&#776;k enerji ihtiyacýný
karþýlayacak du&#776;zeyde beslenememekte, u&#776;ç yaþlýdan 2si bir öðu&#776;nü
atlamaktadýr. 65 yaþ üstü ayaktan hastalarda yetersiz beslenme sýklýðý %30-35
arasýndadýr. Tahmini sýklýk hastanede yatanlarda %70 civarýnda iken,
bakýmevlerinde kalanlarda %85in üzerinde olduðu tahmin edilmektedir. <span
style='color:black'>SVH varlýðýnda baþvuru sýrasýnda %15 hastada, 2. haftada
%22-35 ve takip sýrasýnda %50 hastada malnu&#776;trisyon tanýsý konulmaktadýr. </span>Malnütrisyon,
sýk görülmesinin yaný sýra mortalitede artýþa neden olduðu için de önem arz
etmektedir. Yaþlýlýkta herhangi sebeple kilo kaybýnýn baþlangýcýný takip eden
12,5 yýl içinde, sadece bu sebeple iliþkili olarak mortalite oraný %9-38
artmaktadýr. <span style='color:black'><o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Beslenme durumunu olumsuz etkileyen
faktörler arasýnda yaþlanmayla birlikte ortaya çýkan fizyolojik deðiþiklikler,
akut ve kronik hastalýklar, diþ ve aðýz saðlýðý problemleri, polifarmasi,
ekonomik sorunlar, tek baþýna alýþveriþ yapamama, yemek hazýrlayamama ve
yiyememe gibi çevresel etkenler önemli yer tutar. Ýþtah azalmasýnýn yaþlanma
ile ortaya çýktýðýna dair bazý bulgular mevcuttur ki bu da yaþlanma anoreksisi
olarak bilinmektedir. Yaþlanmayla beraber açlýða ve enerji ihtiyacýna vücudun
verdiði iþtah artýþý cevabýnýn bozulmasý, tat ve koku duyularýndaki
deðiþiklikler, yaþa baðlý olarak geliþen mide boþalma hýzýnýn yavaþlamasý,
ghrelin gibi iþtahla ilgili hormonlarýn dengesindeki deðiþiklikler gibi birçok
faktör nedeniyle iþtahta azalma görülebilir. Ayrýca iþtah, inflamasyon (kanser,
KOAH, kalp yetmezliði gibi) ile birlikte seyreden akut ve kronik hastalýklarda
azalmaktadýr. Ancak diðer taraftan, korku, depresyon, yalnýzlýk ve eþ kaybý
gibi psikososyal sorunlar da iþtahýn azalmasýna sebep olan unsurlardýr.<span
style='color:black'> </span>Kýrýlgan yaþlýlarda çoðunlukla deðiþik faktörler
ayný anda ortaya çýkabilmekte ve kendi aralarýnda etkileþerek gýda alýmýný
etkileyebilmekte ve gýda alýmý ile sindirimi su&#776;recinde akut ve kronik
dönemde dengesizlikler, kilo kaybý ve fonksiyon kaybý gibi durumlar ortaya
çýkabilmektedir.<span style='color:black'><o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Malnütrisyon
Tanýsý<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><span
style='mso-spacerun:yes'> </span><o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:#212121'>Malnütrisyon yaþlý
hastalarda sýk görülmesine raðmen, klinisyenler tarafýndan yeterince tanýnmaz
ve pek çok olguda hasta kaþektik düzeye gelinceye kadar taný ve tedavisi
yapýlamaz. 65 yaþ ve üzeri bireylerde en az yýlda 1 kez ve hastaneye
yatýrýldýklarý her durumda beslenme bozukluðunun deðerlendirilmesi gereklidir
ve uluslararasý kýlavuzlarca önerilmektedir. Öte yandan malnütrisyon tanýsýnda
kullanýlmasý önerilen çok sayýda deðiþik araç/test bulunmaktadýr. Burada
birincil amaç malnütrisyonun en pratik þekilde saptanmasý olmalýdýr. Bu
baðlamda </span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'>ESPEN (</span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>The European
Society of Clinical Nutrition and Metabolism) önerilerine göre </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>vücut</span><span
style='font-family:"Tahoma","sans-serif"'> kitle indeksi (VKÝ) &lt;18,5 kg/m<sup>2
</sup>ise veya herhangi bir zaman diliminde &gt;%10 istemsiz kilo <span
class=GramE>kaybý<span style='mso-spacerun:yes'>  </span>varsa</span>
malnütrisyon tanýsý konur. Ek olarak 3 ay içinde %5 kilo kaybý olmasý ve
beraberinde 70 yaþ altýnda VKÝ &lt;20 kg/m<sup>2</sup>, 70 yaþ ve üzerinde VKÝ
&lt;22 kg/m<sup>2</sup> ise veya yaðsýz VKÝ kadýnda 15 kg/m<sup>2</sup>,
erkekte 17 kg/m<sup>2</sup> ise malnütrisyon tanýsý yine konur.</span><span
style='font-size:9.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%;mso-layout-grid-align:none;text-autospace:none'><span style='font-size:
10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Taný ve tedavideki gecikmelerin önüne geçebilmek ve malnütrisyon
tanýsýnda küresel geçerliliði olan standart yaklaþýmý saðlayabilmek için Eylül
2018de Malnütrisyonda küresel liderlik giriþim topluluðu (Global Leadership
Initiative on Malnutrition - GLIM) yapýsýnda klinik beslenme
organizasyonlarýnýn birçoðu bir araya gelmiþ ve GLIM malnütrisyon <span
class=GramE>kriterlerini</span> yayýnlamýþlardýr.<span
style='mso-spacerun:yes'>  </span>GLIM önerilerine göre birinci basamakta
riskli hastalarý saptamak üzere valide edilmiþ tarama testlerinden birinin
kullanýlmasý önerilir. Bu basamakta Mini-Nütrisyonel Deðerlendirme- Kýsa form
(MNA-SF), Nütrisyonel Risk Taramasý (NRS) veya Malnutrition Universal Screening
Tool (MUST) uygulanabilir. Mini Nütrisyonel Deðerlendirme testi (<b
style='mso-bidi-font-weight:normal'>Tablo 2</b>) yaþlý popu&#776;lasyona özgün
geliþtirilmiþ bir testtir. Ýlk kýsmý 6 sorudan oluþur ve hýzlý bir tarama
testidir. MNA kýsa formdan 12-14 puan alanlarda nütrisyonel durumun normal
olduðu 11 altýnda puan alanlarda ise malnütrisyon riski olduðu söylenir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%;mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%;mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Tablo 2.<span style='mso-spacerun:yes'>  </span></span></b><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Mini Nütrisyonel Deðerlendirme testi</span><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p></o:p></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=533
 style='width:399.95pt;margin-left:5.4pt;border-collapse:collapse;border:none;
 mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:160;mso-padding-alt:
 0cm 5.4pt 0cm 5.4pt;mso-border-insideh:.5pt solid windowtext;mso-border-insidev:
 .5pt solid windowtext'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:9.05pt'>
  <td width=533 colspan=2 valign=top style='width:399.95pt;border:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:9.05pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0cm;
  margin-bottom:3.0pt;margin-left:0cm;text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none'><b><span style='font-size:
  10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:.2pt;background:#D9D9D9;
  mso-shading:windowtext;mso-pattern:gray-15 auto;mso-fareast-language:EN-US'>M</span></b><b><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:-.05pt;
  background:#D9D9D9;mso-shading:windowtext;mso-pattern:gray-15 auto;
  mso-fareast-language:EN-US'>in</span></b><b><span style='font-size:10.0pt;
  mso-bidi-font-size:12.0pt;background:#D9D9D9;mso-shading:windowtext;
  mso-pattern:gray-15 auto;mso-fareast-language:EN-US'>i <span
  style='letter-spacing:-.05pt'>N</span><span style='letter-spacing:.15pt'>ü</span><span
  style='letter-spacing:-.05pt'>trisyone</span>l <span style='letter-spacing:
  -.05pt'>D</span>eð<span style='letter-spacing:.2pt'>e</span><span
  style='letter-spacing:-.05pt'>rlend</span><span style='letter-spacing:.3pt'>i</span><span
  style='letter-spacing:-.05pt'>rm</span>e <span style='letter-spacing:-.05pt'>(</span></span></b><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:.3pt;
  background:#D9D9D9;mso-shading:windowtext;mso-pattern:gray-15 auto;
  mso-fareast-language:EN-US;mso-bidi-font-weight:bold'>M</span><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:-.05pt;
  background:#D9D9D9;mso-shading:windowtext;mso-pattern:gray-15 auto;
  mso-fareast-language:EN-US;mso-bidi-font-weight:bold'>N</span><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:-.25pt;
  background:#D9D9D9;mso-shading:windowtext;mso-pattern:gray-15 auto;
  mso-fareast-language:EN-US;mso-bidi-font-weight:bold'>A</span><b><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;background:#D9D9D9;
  mso-shading:windowtext;mso-pattern:gray-15 auto;mso-fareast-language:EN-US'>)
  1.Kýsým<span style='letter-spacing:.2pt;background:lightgrey;mso-highlight:
  lightgrey'><o:p></o:p></span></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:47.0pt'>
  <td width=264 valign=top style='width:197.75pt;border:solid windowtext 1.5pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:47.0pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'>1. Son üç a<span style='letter-spacing:-.25pt'>y</span>da
  iþtahsýzlýða, sindi<span style='letter-spacing:-.3pt'>r</span><span
  style='letter-spacing:.25pt'>i</span>m <span style='letter-spacing:-.3pt'>s</span><span
  style='letter-spacing:.25pt'>o</span><span style='letter-spacing:-.3pt'>r</span>un<span
  style='letter-spacing:-.15pt'>l</span><span style='letter-spacing:.25pt'>a</span><span
  style='letter-spacing:-.25pt'>rý</span><span style='letter-spacing:.3pt'>n</span>a,
  çiðneme ya da yutma <span style='letter-spacing:-.25pt'>z</span>or<span
  style='letter-spacing:-.25pt'>l</span><span style='letter-spacing:.3pt'>u</span>kla<span
  style='letter-spacing:-.2pt'>rý</span>na b<span style='letter-spacing:.1pt'>aðlý
  </span>o<span style='letter-spacing:-.2pt'>l</span><span style='letter-spacing:
  .25pt'>a</span><span style='letter-spacing:-.3pt'>r</span><span
  style='letter-spacing:.25pt'>a</span>k besin <span style='letter-spacing:
  .05pt'>a</span><span style='letter-spacing:-.25pt'>lýmýn</span><span
  style='letter-spacing:.05pt'>d</span>a <span style='letter-spacing:.05pt'>bi</span>r
  <span style='letter-spacing:.25pt'>a</span><span style='letter-spacing:-.3pt'>z</span><span
  style='letter-spacing:.25pt'>a</span><span style='letter-spacing:.05pt'>l</span><span
  style='letter-spacing:-.15pt'>m</span>a <span style='letter-spacing:.05pt'>o</span><span
  style='letter-spacing:-.25pt'>l</span><span style='letter-spacing:.05pt'>d</span>u
  <span style='letter-spacing:.05pt'>m</span><span style='letter-spacing:.2pt'>u</span></span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>?
  <o:p></o:p></span></p>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>                 
  </span>0 = C<span style='letter-spacing:-.45pt'>i</span>d<span
  style='letter-spacing:.25pt'>d</span>i iþtah k<span style='letter-spacing:
  .2pt'>a</span><span style='letter-spacing:-.25pt'>y</span><span
  style='letter-spacing:.05pt'>bý</span><o:p></o:p></span></p>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>                 
  </span>1 = O<span style='letter-spacing:-.2pt'>r</span><span
  style='letter-spacing:.25pt'>t</span>a düze<span style='letter-spacing:-.55pt'>y</span><span
  style='letter-spacing:.25pt'>d</span>e iþtah k<span style='letter-spacing:
  .2pt'>a</span><span style='letter-spacing:-.25pt'>y</span><span
  style='letter-spacing:.05pt'>bý</span><o:p></o:p></span></p>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>                 
  </span>2 = Ýþtah k<span style='letter-spacing:.2pt'>a</span><span
  style='letter-spacing:-.25pt'>y</span><span style='letter-spacing:.05pt'>bý</span><span
  style='letter-spacing:-.3pt'> y</span><span style='letter-spacing:.25pt'>o</span>k<o:p></o:p></span></p>
  </td>
  <td width=270 valign=top style='width:202.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext 1.5pt;mso-border-left-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.0pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'>4. Son 3 a<span style='letter-spacing:-.2pt'>y</span>da
  psiko<span style='letter-spacing:-.35pt'>l</span>ojik stres ya da akut hasta<span
  style='letter-spacing:-.2pt'>lýk</span>tan <span class=GramE>þi<span
  style='letter-spacing:-.2pt'>k</span>ayet</span> o<span style='letter-spacing:
  -.35pt'>l</span>du mu?</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='line-height:6.5pt;mso-line-height-rule:exactly;
  mso-pagination:none;mso-layout-grid-align:none;text-autospace:none'><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;letter-spacing:-.05pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>          </span>0 </span><span style='font-size:
  8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>= <span
  style='letter-spacing:.15pt'>E</span><span style='letter-spacing:-.25pt'>v</span><span
  style='letter-spacing:-.05pt'>et</span><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>         
  </span>2 = <span style='letter-spacing:-.05pt'>H</span><span
  style='letter-spacing:.2pt'>a</span><span style='letter-spacing:-.2pt'>yýr</span><o:p></o:p></span></p>
  <p class=MsoNormal><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:38.85pt'>
  <td width=264 valign=top style='width:197.75pt;border:solid windowtext 1.5pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:38.85pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  letter-spacing:.05pt;mso-fareast-language:EN-US'>2</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>.
  <span style='letter-spacing:.05pt'>So</span>n <span style='letter-spacing:
  .05pt'>ü</span>ç <span style='letter-spacing:.05pt'>a</span>y <span
  style='letter-spacing:.05pt'>içinde</span><span style='letter-spacing:-.3pt'>k</span>i
  <span style='letter-spacing:-.2pt'>k</span><span style='letter-spacing:.05pt'>i</span><span
  style='letter-spacing:-.2pt'>l</span>o <span style='letter-spacing:-.2pt'>k</span><span
  style='letter-spacing:.05pt'>ay</span>bý <span style='letter-spacing:.05pt'>du</span><span
  style='letter-spacing:-.25pt'>r</span><span style='letter-spacing:.3pt'>u</span><span
  style='letter-spacing:-.15pt'>m</span>u</span></b><span style='font-size:
  8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>              </span>0 = Üç kg<span
  style='letter-spacing:.1pt'></span>dan <span style='letter-spacing:-.4pt'>f</span>azla
  ki<span style='letter-spacing:-.3pt'>l</span>o k<span style='letter-spacing:
  .2pt'>a</span><span style='letter-spacing:-.25pt'>y</span>bý<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>              </span>1 = <span style='letter-spacing:
  .25pt'>B</span><span style='letter-spacing:-.3pt'>i</span>l<span
  style='letter-spacing:-.2pt'>i</span><span style='letter-spacing:.25pt'>n</span><span
  style='letter-spacing:-.2pt'>m</span>i<span style='letter-spacing:-.5pt'>y</span><span
  style='letter-spacing:.25pt'>or</span><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>              </span>2 = 1 <span style='letter-spacing:
  -.3pt'>v</span>e 3kg ara<span style='letter-spacing:-.15pt'>sý</span><span
  style='letter-spacing:-.25pt'>n</span>da <span style='letter-spacing:.2pt'>k</span>i<span
  style='letter-spacing:-.45pt'>l</span>o k<span style='letter-spacing:.2pt'>a</span><span
  style='letter-spacing:-.25pt'>y</span><span style='letter-spacing:.05pt'>bý</span><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>              </span>3 = Ki<span style='letter-spacing:
  -.6pt'>l</span>o k<span style='letter-spacing:.35pt'>a</span><span
  style='letter-spacing:-.25pt'>y</span>bý <span style='letter-spacing:-.3pt'>y</span><span
  style='letter-spacing:.25pt'>o</span>k<o:p></o:p></span></p>
  </td>
  <td width=270 valign=top style='width:202.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext 1.5pt;mso-border-left-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:38.85pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'>5. Nö<span style='letter-spacing:-.3pt'>r</span>o-ps<span
  style='letter-spacing:.2pt'>i</span><span style='letter-spacing:-.2pt'>k</span>o<span
  style='letter-spacing:-.2pt'>l</span>oj<span style='letter-spacing:.35pt'>i</span>k
  p<span style='letter-spacing:-.25pt'>r</span>o<span style='letter-spacing:
  .3pt'>b</span><span style='letter-spacing:-.2pt'>l</span><span
  style='letter-spacing:.2pt'>e</span>mle<span style='letter-spacing:-.25pt'>r</span>:</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>        
  </span>0 = C<span style='letter-spacing:-.4pt'>i</span>d<span
  style='letter-spacing:.25pt'>d</span>i <span style='letter-spacing:-.25pt'>b</span><span
  style='letter-spacing:.25pt'>u</span><span style='letter-spacing:-.25pt'>n</span><span
  style='letter-spacing:.2pt'>a</span><span style='letter-spacing:-.2pt'>m</span>a
  ve depre<span style='letter-spacing:.25pt'>s</span><span style='letter-spacing:
  -.5pt'>y</span><span style='letter-spacing:.45pt'>o</span>n<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>        
  </span>1 = Haf<span style='letter-spacing:-.35pt'>i</span>f düzeyde <span
  style='letter-spacing:-.25pt'>b</span><span style='letter-spacing:.25pt'>u</span><span
  style='letter-spacing:-.25pt'>n</span><span style='letter-spacing:.2pt'>a</span><span
  style='letter-spacing:-.2pt'>m</span>a ve depresyon<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>        
  </span>2 = H<span style='letter-spacing:-.35pt'>i</span><span
  style='letter-spacing:.2pt'>ç</span>b<span style='letter-spacing:-.45pt'>i</span>r
  nöropsik<span style='letter-spacing:.4pt'>o</span><span style='letter-spacing:
  -.45pt'>l</span><span style='letter-spacing:.45pt'>o</span><span
  style='letter-spacing:-.2pt'>ji</span>k pr<span style='letter-spacing:.25pt'>o</span>b<span
  style='letter-spacing:-.45pt'>l</span><span style='letter-spacing:.2pt'>e</span>m
  <span style='letter-spacing:-.5pt'>y</span><span style='letter-spacing:.25pt'>o</span>k<o:p></o:p></span></p>
  <p class=MsoNormal><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:44.2pt'>
  <td width=264 valign=top style='width:197.75pt;border:solid windowtext 1.5pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:44.2pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  letter-spacing:.1pt;mso-fareast-language:EN-US'>3</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>.
  <span style='letter-spacing:.1pt'>Mobilite</span></span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;letter-spacing:-.05pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>              </span>0 </span><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>=
  <span style='letter-spacing:-.05pt'>Ya</span><span style='letter-spacing:
  .25pt'>t</span><span style='letter-spacing:-.05pt'>a</span>k <span
  style='letter-spacing:-.45pt'>y</span>a <span style='letter-spacing:-.05pt'>d</span>a
  <span style='letter-spacing:-.05pt'>sanda</span><span style='letter-spacing:
  .15pt'>l</span><span style='letter-spacing:-.25pt'>y</span><span
  style='letter-spacing:.2pt'>e</span><span style='letter-spacing:-.25pt'>y</span>e
  <span style='letter-spacing:-.05pt'>b</span>aðýmlý<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>              </span>1 = Yataktan, s<span
  style='letter-spacing:-.2pt'>a</span><span style='letter-spacing:-.25pt'>n</span>d<span
  style='letter-spacing:.2pt'>a</span>l<span style='letter-spacing:-.2pt'>y</span>eden
  kalkabili<span style='letter-spacing:-.35pt'>y</span><span style='letter-spacing:
  .25pt'>o</span>r<span style='letter-spacing:.1pt'> </span><span class=GramE><span
  style='letter-spacing:.25pt'>a</span><span style='letter-spacing:-.45pt'>m</span>a<span
  style='mso-spacerun:yes'>  </span>dýþarýya</span> çýkamýyor<span
  style='letter-spacing:.1pt'><o:p></o:p></span></span></p>
  <p class=MsoNormal><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>                    </span>2 = Dýþarý <span
  style='letter-spacing:.3pt'>çý</span><span style='letter-spacing:.25pt'>ka</span><span
  style='letter-spacing:-.05pt'>b</span><span style='letter-spacing:-.2pt'>i</span>li<span
  style='letter-spacing:-.5pt'>y</span><span style='letter-spacing:.25pt'>or</span><o:p></o:p></span></p>
  </td>
  <td width=270 valign=top style='width:202.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext 1.5pt;mso-border-left-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:44.2pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  letter-spacing:-.05pt;mso-fareast-language:EN-US'>6</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>.
  Vücut <span style='letter-spacing:.3pt'>B</span><span style='letter-spacing:
  -.05pt'>ede</span>n k<span style='letter-spacing:-.05pt'>i</span><span
  style='letter-spacing:.15pt'>t</span><span style='letter-spacing:-.05pt'>l</span>e
  i<span style='letter-spacing:-.05pt'>n</span><span style='letter-spacing:
  .15pt'>d</span><span style='letter-spacing:-.05pt'>ek</span><span
  style='letter-spacing:-.25pt'>s</span>i <span style='letter-spacing:.25pt'>(</span><span
  style='letter-spacing:-.05pt'>B</span><span style='letter-spacing:.25pt'>K</span><span
  style='letter-spacing:-.1pt'>Ý</span>) <span style='letter-spacing:-.05pt'>(kg/m2)<span
  style='mso-spacerun:yes'>     </span></span></span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;letter-spacing:.55pt;
  mso-fareast-language:EN-US'>veya</span><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>         
  </span>0 = <span style='letter-spacing:.1pt'>&lt;</span>19<span
  style='mso-spacerun:yes'>                               </span><span
  style='mso-spacerun:yes'>          </span>Baldýr Çevresi<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>         
  </span>1 = <span style='letter-spacing:.1pt'>&#8805;</span>19 ve &lt;21<span
  style='mso-spacerun:yes'>                                    </span>ölçümü<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>         
  </span>2 = <span style='letter-spacing:.1pt'>&#8805;</span>21 ve &lt;23<span
  style='mso-spacerun:yes'>                                   </span>&#8805;<span
  style='mso-spacerun:yes'>   </span><span class=GramE>31 : 3</span><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>         
  </span>3 = <span style='letter-spacing:.1pt'>&#8805;</span>23<span
  style='mso-spacerun:yes'>                                              
  </span>&lt;<span style='mso-spacerun:yes'>  </span><span class=GramE>31 : 0</span><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes;height:5.4pt'>
  <td width=533 colspan=2 valign=top style='width:399.95pt;border:solid windowtext 1.5pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;mso-layout-grid-align:none;text-autospace:none'><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>Toplam
  Puan<span class=GramE><span style='letter-spacing:-.05pt'>:</span><span
  style='letter-spacing:-.05pt;font-weight:normal'>..</span></span></span></b><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;letter-spacing:-.05pt;mso-fareast-language:EN-US'>/14</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;letter-spacing:.15pt;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>       </span>Ý</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;letter-spacing:-.05pt;
  mso-fareast-language:EN-US'>zle</span></b><b><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>m <span
  style='letter-spacing:-.05pt'>D</span>eð<span style='letter-spacing:.2pt'>e</span><span
  style='letter-spacing:-.05pt'>rlen</span><span style='letter-spacing:.2pt'>d</span><span
  style='letter-spacing:-.05pt'>irm</span><span style='letter-spacing:.15pt'>e</span><span
  style='letter-spacing:-.05pt'>si :<span style='mso-spacerun:yes'>    </span></span></span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;font-family:Wingdings;
  mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
  mso-fareast-language:EN-US;mso-char-type:symbol;mso-symbol-font-family:Wingdings;
  mso-bidi-font-weight:bold'><span style='mso-char-type:symbol;mso-symbol-font-family:
  Wingdings'>o</span></span><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'> </span><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;mso-fareast-font-family:MyriadPro-Light;mso-fareast-language:
  EN-US'>0-7<span style='mso-spacerun:yes'>  </span>malnütrisyon<span
  style='mso-spacerun:yes'>         </span></span><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;font-family:Wingdings;mso-ascii-font-family:"Times New Roman";
  mso-hansi-font-family:"Times New Roman";mso-fareast-language:EN-US;
  mso-char-type:symbol;mso-symbol-font-family:Wingdings;mso-bidi-font-weight:
  bold'><span style='mso-char-type:symbol;mso-symbol-font-family:Wingdings'>o</span></span><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>
  </span><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-font-family:
  MyriadPro-Light;mso-fareast-language:EN-US'>8-11 malnütrisyon riski<span
  style='mso-spacerun:yes'>         </span></span><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;font-family:Wingdings;mso-ascii-font-family:"Times New Roman";
  mso-hansi-font-family:"Times New Roman";mso-fareast-language:EN-US;
  mso-char-type:symbol;mso-symbol-font-family:Wingdings;mso-bidi-font-weight:
  bold'><span style='mso-char-type:symbol;mso-symbol-font-family:Wingdings'>o</span></span><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>
  </span><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-font-family:
  MyriadPro-Light;mso-fareast-language:EN-US'>&gt;11 normal<span
  style='mso-spacerun:yes'>    </span><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%;mso-layout-grid-align:none;text-autospace:none'><span style='font-size:
10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Riskli bireyler saptandýktan sonra
malnütrisyon tanýsýný deðerlendirmek üzere fenotipik ve etyolojik <span
class=GramE>kriterlerin</span> varlýðý araþtýrýlýr. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Fenotipik <span class=GramE>kriterler</span>:
Son altý ay içinde %5 veya 6 aydan uzun sürede %10 kilo kaybýnýn olmasý, düþük
VKÝnin olmasý (&lt;70 yaþ: &lt;20 kg/m2 veya &gt;70 yaþ : &lt;22 kg/m2 Asyada
&lt;70 yaþ : &lt;18,5 kg/m2 veya &gt;70 yaþ &lt;20 kg/m2) ve/veya azalmýþ kas
kütlesi olmasý (Valide edilmiþ vücut bileþeni ölçüm teknikleri ile): örneðin
bioimpedans DXA, MRI, BT gibi<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Etyolojik kriterler: azalmýþ besin
alýmý/sindirimi (&gt;1 hafta &lt;=%50 enerji ihtiyacý veya &gt;2 hafta herhangi
bir <span class=GramE>azalma,</span> veya gýdalarýn sindirimini ya da emilimini
olumsuz etkileyen kronik bir gastrointestinal durum) ve/veya inflamasyon (Akut
hastalýk/yaralanma veya kronik hastalýða baðlý). Malnütrisyon tanýsý koyabilmek
için etyolojik <span class=GramE>kriterlerden</span> en az biri ve fenotipik
kriterlerden en az birinin var olmasý gerekir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Malnütrisyonun ciddiyetini belirlemek
için fenotipik <span class=GramE>kriterler</span> kullanýlýr. Bu basamakta kilo
kaybý son 6 ay içinde %5-10 veya 6 aydan uzun sürede %10-20 ise evre 1 (ýlýmlý
malnütrisyon), son 6 ay içinde &gt;%10 veya 6 aydan uzun sürede &gt;%20 ise
evre 2 (þiddetli malnütrisyondan) bahsedilir. Eðer hastanýn VKÝ &lt;70 yaþta
&lt;20 kg/m2,&gt;=70 yaþta &lt;22 kg/m2 ise evre 1 malnütrisyon, &lt;70 yaþta
&lt;18,5 kg/m2 &gt;=70 yaþta &lt;20 kg/m2 ise evre 2 malnütrisyon olarak
derecelendirilir. Kas kütlesinde hafif ila orta azalma var ise evre 1
malnütrisyon, þiddetli azalma var ise evre 2 malnütrisyon olarak
deðerlendirilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Beslenme yetersizliði sorgulanan bir
hastada bireyin beslenme alýþkanlýðý nitelik ve içerik açýsýndan sorgulanmalý, ishal
kusma gibi sindirim sistemi bulgularý sorulmalý ve hastanýn kullandýðý ilaçlar,
mevcut hastalýklarý, alýþkanlýklarý öðrenilmelidir. Kilo kaybý olanlarda altta
yatan sebebi araþtýrmak için tam kan sayýmý, glukoz, elektrolitler, böbrek ve
karaciðer fonksiyon testleri, tiroid fonksiyon testi, sedimentasyon, tam idrar
tahlili ve akciðer grafisi rutin istenmesi gereken testlerdir. Bu testler
dýþýnda hastanýn bulgularýna göre daha ileri tetkikler planlanabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'>ESPEN önerilerine göre PH olanlarda hastalýk
süresince beslenme ve vitamin durumunun düzenli olarak izlenmesi tavsiye
edilir. Kilo kaybý, düþük VKÝ, demans veya disfaji bulgularý olan Parkinson
hastalarýnda on fazýnda iken disfaji varlýðý taranmalýdýr. Taramada PHna
özel anketler </span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:Symbol;mso-ascii-font-family:Tahoma;mso-hansi-font-family:Tahoma;
mso-bidi-font-family:Tahoma;color:black;mso-themecolor:text1;mso-char-type:
symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:symbol;
mso-symbol-font-family:Symbol'>[</span></span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1'>örneðin SDQ (swallowing disturbance questionnaire) veya
MDT-PD (<span style='background:white'>Munich Dysphagia Test</span>)</span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-ascii-font-family:Tahoma;mso-hansi-font-family:Tahoma;mso-bidi-font-family:
Tahoma;color:black;mso-themecolor:text1;mso-char-type:symbol;mso-symbol-font-family:
Symbol'><span style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>]</span></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'> ve yutma tarama testleri önerilir. Yutma
tarama testlerinden akut inmede kullanýlmasý önerilen su yutma testinin PHde
orofaringeal disfajiyi öngöremediði saptanmýþtýr. Ýstanbul Týp Fakültesi
Geriatri Bilim Dalý pratiðinde de kullanýlmakta olan Volüm-Viskozite Yutma
Testi (VVST) ise PHde valide edilmiþtir. Taramada disfaji saptanan, hastalýðýn
hýzlý kötüleþmesi olan, pnömonisi olan veya disfajinin diðer bulgularý olan
hastalarda enstrümental disfaji testi yapýlmalýdýr. Deðerlendirme fiberoptik
endoskopik yutma deðerlendirmesi (fiberoptic endoscopic evaluation of
swallowing) (FEES) <span class=GramE>ile,</span> eðer bu yapýlamýyor ise
Videofluoroscopic assessment of swallowing (VFA) ile yapýlmalýdýr. Enstrümental
deðerlendirme yapýlamýyorsa klinik deðerlendirme yapýlmalýdýr. PH için
kullanýlan ilaçlarýn yan etkileri beslenme durumunu etkileyebilir. Levodopa
kullananlarda homosistein ve B6 vitamini durumuna özellikle dikkat edilmelidir.
Levodopa homosistein düzeyinde artýþa neden olur. Parkinson hastalarýnda
dopaminerjik ilaçlarýn bulantý kusma yapabileceði, vitamin desteði altýndaki
hastalarda B6 vitamininin levodopa emilimini bozabileceði, insu&#776;lin
salýnýmýnýn levodopanýn kan beyin bariyerini geçmesini kolaylaþtýrdýðý, bu
nedenle diyetteki karbonhidrat oranýnýn yu&#776;ksek olmasýnýn faydalý
olabileceði unutulmamalýdýr. Ayrýca PH tedavisinde kullanýlan levadopa aç
karnýna (yemeklerden en az 1 saat önce ya da yemeklerden 2-3 saat sonra)
alýnmalýdýr.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'>Tüm <b style='mso-bidi-font-weight:normal'>inme</b>
hastalarý disfaji, bilinç bozukluðu, algý bozukluðu ve kognitif iþlev bozukluðu
nedeniyle malnütrisyon ve dehidratasyona yatkýn olabilir. Malnütrisyonda ya da
malnütrisyon riski altýnda olma, artmýþ mortalite riski ve diðer kötü
sonuçlarla iliþkilidir.</span><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'> Ayrýca, inme
hastalarý hayatý tehdit eden bir <span class=GramE>komplikasyon</span> olan
aspirasyon pnömonisi için de yüksek risk altýndadýr. </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>ESPEN
önerilerine göre tüm inme geçiren hastalarda mümkün olan en kýsa sürede disfaji
taramasý <span style='color:black;mso-themecolor:text1'>yapýlmalýdýr. Disfaji
taramasý yapýlamayan veya öksürme, boðulma, ýslak ses, aðýz içinde yiyecek
kalýntýlarý kalmasý veya pnömoni varlýðý gibi disfaji <span class=GramE>semptomlarý</span>
gösteren veya dizartri, afazi, fasyal paralizi, kognitif bozukluk, bilinç
bozukluðu gibi disfaji risk faktörleri olan tüm inme hastalarýnýn yutma
fonksiyonu mümkün olan en erken zamanda deðerlendirilmelidir. <o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Tanýsal
yaklaþým aspirasyon taramalarýndan olan su yutma testi <span style='color:#212121'>ile
baþlar. <span style='background:white'>Daha kapsamlý bir deðerlendirme söz
konusu olduðunda enstrümental deðerlendirmelerden</span></span><span
style='color:black;mso-themecolor:text1;background:white'> VFA </span><span
style='color:#212121;background:white'>veya FEES gerçekleþtirilebilir. FEESin
bazý avantajlarý vardýr. Bu testte hastanýn minimum iþbirliðine ihtiyaç
duyulur.</span> Tüm inmeli hastalar hastane baþvurusunda (ilk 48 saat içinde)
malnütrisyon riski açýþýndan deðerlendirilmelidir. Bu amaçla týbbi beslenme
tedavisinden yararlanma olasýlýðý daha yüksek olan hastalarý belirlemek için<span
style='color:red'> </span><span style='color:black;mso-themecolor:text1'>MUST
testi </span>kullanýlabilir. Disfajisi olmayan ve yeterli beslenen hastalara
rutin oral nütrisyon desteði önerilmez. Yemek yiyebilen ve malnütrisyon veya
malnütrisyon riski olanlarda oral nütrisyon desteði önerilir. Disfaji saptanan
hastalarda kývamý deðiþtirilmiþ gýdalar veya katýlaþtýrýlmýþ sývýlar aspirasyon
pnömonisi insidansýný azaltýr. D<span style='color:#212121'>isfajinin
deðerlendirilmesi ve tedavisi konusunda deneyimli profesyoneller tarafýndan
standart bir protokole göre aspirasyon riskini de içeren yutma iþlevinin
deðerlendirilmesinden sonra </span>kývamý deðiþtirilmiþ gýdalar <span
style='color:#212121'>ve koyulaþtýrýlmýþ sývýlar verilmelidir. Bu deðerlendirme
normal yutma fonksiyonu tekrar elde edilinceye kadar düzenli aralýklarla
tekrarlanmalýdýr. </span><span style='color:black;mso-themecolor:text1'>Gazlý
içecekler koyulaþtýrýlmýþ sývýlara kýyasla farengeal artýðý azaltabilir. Gazlý
içeceklerin kullanýmý, farengeal kalýntý teþhisi konan inme hastalarý için bir
seçenek olabilir. <span style='background:white'>Ýnme sonrasý uzamýþ þiddetli
disfajisi olan ve disfajinin 7 günden uzun sürmesi beklenen hastalarda 3 gün
içinde enteral tüp beslenmesi önerilir. </span></span>Bilinç seviyesi düþük
olan ve mekanik ventilasyon ihtiyacý olan kritik inme hastalarýnda enteral
tüple beslenmeye <span style='color:black;mso-themecolor:text1'>3 gün içinde
geçilmelidir. </span><span style='color:#212121;background:white'>Eðer inmenin
akut fazý sýrasýnda yeterli oral besin alýmý mümkün deðilse, enteral nütrisyon
tercihen nazogastrik tüp ile verilmelidir. </span><span
style='mso-spacerun:yes'> </span><span style='color:#212121;background:white'>Eðer
enteral beslenme daha uzun bir süre için gerekliyse (&gt; 28 gün), PEG
seçilmeli ve PEG <span class=GramE>stabil</span> bir klinik dönemde
yerleþtirilmelidir (14-28 gün sonra).</span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>ESPEN
önerilerine göre <b style='mso-bidi-font-weight:normal'>demans</b>ý<b
style='mso-bidi-font-weight:normal'> </b>olan her hasta malnütrisyon açýsýndan
taranmalýdýr. Demanslý hastalarýn kilosu yakýn takip edilmeli ve
belgelenmelidir. <span style='color:#212121;background:white'>Kiþisel
tercihlere önem vererek bireysel ihtiyaçlara göre yeterli yiyecek tedariki
önerilmektedir.</span> <span style='color:#212121'>Ýþtah uyarýcýlarýn kullanýmý
önerilmez.</span> Demanslý hastalarda <span style='color:#212121;background:
white'>malnütrisyonun olasý nedenlerinin olabildiðince ortadan kaldýrýlmasý
gerekir.</span> <span style='color:black;mso-themecolor:text1'>Diyet</span>
kýsýtlamalarýndan uzak durulmalýdýr. <span style='color:#212121'>Demanslý
kiþilerde kognitif bozukluða yönelik omega-3-yað asidi, B1 vitamini, B12
vitamini, B6 vitamini ve/veya folik asit takviyelerinin kullanýlmasý önerilmez.</span>
<span style='color:#212121;background:white'>Kognitif yýkýmýn önlenmesi veya
düzeltilmesi için bunama hastalarýnda E vitamini, selenyum, bakýr, D vitamini
takviyelerinin kullanýlmasý önerilmez. Demansý olan kiþilere kognitif bozukluðu
düzeltmek veya kognitif gerilemeyi önlemek için özel týbbi gýdalarýn kullanýmý
da önerilmez. Bununla birlikte </span><span style='color:#212121'>yapýlan
çalýþmalarda<span style='background:white'> </span>Multinutrient Fortasyn
Connect (</span><span style='color:#333333;background:white'>Omega-3 (günlük
1500 mg d</span><em><span style='font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1;background:white;mso-bidi-font-weight:bold;font-style:
normal'>okosaheksaenoik asit</span></em><span style='color:black;mso-themecolor:
text1'> </span><span style='color:#333333;background:white'>eikosapentaenoik asit),
fosfolipidler, kolin, yüksek doz vitamin B (B12, <span class=GramE>B6,</span>
ve folik asit), vitamin E, vitamin C, selenyum, ve uridin monofosfat) </span><span
style='color:#212121'>alan Alzheimer hastalarýnda kognitif iþlevlerde göreceli
bir iyilik ve beyin atrofi hýzýnda azalma olabileceði öne sürülmüþtür. <span
style='background:white'>Malnütrisyon riski veya malnütrisyonu olan </span>demanslý
hastalarda </span><span style='color:black;mso-themecolor:text1'>beslenme
durumunu iyileþtirmek için </span><span style='color:#212121'>oral nütrisyonel
ek kullanýmý önerilir.</span> Eðer düþük besinsel alým büyük ölçüde <span
style='color:black;mso-themecolor:text1'>düzeltilebilir </span>bir durumdan
kaynaklanýyorsa, akut duru<span style='color:black;mso-themecolor:text1'>mun</span>
üstesinden gelmek için malnütrisyonu olan hafif-orta <span class=GramE>demanslý<span
style='mso-spacerun:yes'>  </span>hastalarda</span> sýnýrlý bir süre için tüple
beslenme önerilir. <span style='color:#212121;background:white'>Ýleri evre
demanslý hastalarda ise tüp beslenmesi önerilmez.</span> Eðer yapay beslenme
endikasyonu var fakat tüple beslenme kontrendike ise veya tolere edilemiyorsa
parenteral nütrisyon önerilir. Hayatýn terminal döneminde yapay beslenme
(enteral beslenme, parenteral beslenme ve parenteral sývý) önerilmez.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Malnütrisyonda
tedavi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Tarama
ve deðerlendirme sonucunda malnu&#776;trisyon veya malnu&#776;trisyon riski
tespit edilen hastalara beslenme destek tedavisi planlanmalýdýr. Hastalarýn
metabolik gereksinimine göre kalori alýmýnýn yeterli olup olmadýðýna
bakýlmalýdýr. Öncelikle oral gýda <span class=GramE>alýmý mu</span>&#776;mku&#776;n
olanlarda gu&#776;nlu&#776;k kalori ihtiyacý doðrultusunda diyet du&#776;zenlenir.
Diyet ile yeterli kalori alýmý saðlanamaz ise enteral ve/veya parenteral
beslenme u&#776;ru&#776;nleri ile destek tedavi baþlanabilir. Bu tedavi
modalitesinde asýl olan enteral beslenmedir, fakat bu her zaman yeterli veya
uygulanabilir olamayabilir, dolayýsýyla bazen parenteral nu&#776;trisyon
tedavisi ile destek gerekmektedir. Enteral beslenme yollarý oral enteral,
nazoenteral ve enteroku&#776;tan yollardýr. Enteral beslenmede kullanýlacak
yöntem beklenen beslenme süresi, aspirasyon riski ve sindirim sisteminin
durumuna göre belirlenmelidir. Nazoenteral yol için nazogastrik veya
nazointestinal feeding tu&#776;p kullanýlabilir. Bu tu&#776;plerin silikon
veya poliu&#776;retan olanlarý tercih edilmelidir. Enteroku&#776;tan yollar
ise, perku&#776;tan endoskopik gastrostomi (PEG) ve perku&#776;tan endoskopik
jejunostomidir (PEJ). Otuz günden kýsa beslenme için nazogastrik ve
nazointestinal tüpler kullanýlabilir. Küçük çaplý feeding tüpleri nazogastrik
tüplere göre daha iyi tolere edilir. Nörolojik disfaji varlýðýnda enteral
beslenme yollarýndan birinin tercih edilmesi, lif içerikli u&#776;ru&#776;nlerin
seçilmesi, basý yaralarý varlýðýnda yu&#776;ksek protein içerikli u&#776;ru&#776;nlerin
verilmesi önerilmektedir. Erken ve orta evredeki demans hastalarýnda oral veya
tu&#776;ple beslenme tedavisi verilmesi, ileri evre demans hastalarýnda tu&#776;ple
beslenmenin tercih edilmemesi gerekir. Terminal evre kanser hastalarýnda da tu&#776;ple
beslenmenin uygulanmamasý önerilmektedir. Uzun su&#776;reli tu&#776;ple
beslenme gereken hastalarda (&gt;4 hafta) PEG uygulanmasý tavsiye edilmektedir.
PEG iþleminin <span class=GramE>komplikasyon</span> riski azdýr, infeksiyon,
kanama ve peritonit %1-3 arasýnda rapor edilmiþtir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Beslenme
yolu seçildikten sonra gu&#776;nlu&#776;k enerji ihtiyacý (GEÝ) hesaplanmalý ve
ardýndan oral gýda alýmý da göz önünde bulundurularak gu&#776;nlu&#776;k
verilecek destek miktarý hesaplanmalýdýr. GEÝnýn ortalama 25-30 kcal/kg/gün,
obezlerde 20-25 kcal/kg, stres durumunda 30-40 kcal/kg, sepsis durumunda 40-50
kcal/kg þeklinde hesaplanmasý önerilir. Hafif þiddette hastalýkta bazal
metabolizma hýzýnýn 1,3 katý, orta þiddette hastalýkta 1,5 katý ve ciddi
þiddette hastalýkta 1,7-1,8 katý kadar enerji alýmýna ihtiyaç vardýr. GEÝ
hesaplandýktan sonra hastaya yediklerini listelemesi istenir ve bu liste u&#776;zerinden
gu&#776;nlu&#776;k almakta olduðu kalori miktarý hesaplanýr. Günlük enerji
ihtiyacýndan almakta olduðu kalori miktarý çýkarýlarak enerji açýðý hesaplanýr.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Yaþlýlarda
fiziksel fonksiyonu yerine getirmek için gençlere göre daha fazla protein
ihtiyacý vardýr.<span style='mso-spacerun:yes'>  </span>PROT-AGE Grubu günlük
ortalama protein gereksinimi 1-1,2 g/kg arasýnda olmasý gerektiðini bildirmiþtir.
Akut veya kronik hastalýðý olan yaþlýlarda ise daha fazla proteine ihtiyaç
olduðu (örn: 1,2-1,4 g/kg) ciddi hastalýðý olan, yaralanma veya belirgin
malnütrisyonu olanlarda 2 g/kga kadar ihtiyaç olabileceði belirtilmiþtir.
Ciddi böbrek yetmezliði olan ve diyalize girmeyen hastalarda (örn, eGFR &lt;30
mL/min/1,73m2) protein alýmý kýsýtlanmalýdýr (0,8 g/kg/g). Orta böbrek
yetmezliðinde (GFR 30-60 mL/min/1,73m 2) &gt; 0,8 g/kg/g güvenlidir fakat GFR
yýlda iki defa takip edilmelidir. Hemodiyaliz ve periton diyalizine girenlerde
protein alýmý&gt; 1,2 g/kg/g olmalýdýr, eðer ulaþýlabiliyorsa 1,5 g/kg/ g e
kadar çýkarýlabilir.<span style='mso-spacerun:yes'>  </span>PROT-AGE çalýþma
grubu, egzersizden hemen sonra <span class=GramE>amino</span> asitlere kas
duyarlýlýðý arttýðý için, fiziksel egzersizden hemen sonra protein alýmýný önerir.<span
style='mso-spacerun:yes'>  </span>Göz ardý edilmemesi gereken bir diðer önemli
nokta da yaþlýlarýn yemeklerindeki dengesiz protein daðýlýmý ve sýk sýk öðün
atlanmasýdýr. Günlük protein alýmýnýn, alýnan proteinden <span class=GramE>optimal</span>
fayda saðlamak için, gün boyunca yemeklerle orantýlý olarak daðýtýlmasý
gerekir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Oral
beslenmede öncelikle oral gýda alýmý arttýrýlmalýdýr. Yapýlan öneriler yaþlýnýn
alýþkanlýklarýna uygun olmalýdýr. Enerji ve protein içeriði düþük gýdalar
kaliteli gýdalarla deðiþtirilmelidir. Yemek aralarýnda atýþtýrmalýklar önerilmelidir.
Oral gýda alýmýný arttýrmaya yönelik önlemler baþarýsýz olursa oral nütrisyonel
ürünlere vakit kaybetmeden baþlanmalýdýr.<span style='mso-spacerun:yes'> 
</span>Enteral beslenme ürünlerinin hepsi protein, karbonhidrat ve yaðlardan
oluþur. Ürünler arasýndaki farklýlýklar sindirilebilirlik, kývam, ozmolarite,
içeriklerin miktarý ve fiyatýna göredir. Ýzotonik formüller (1-1,2 kcal/ml)
genelde baþlangýçta kullanýlan ürünlerdir. Daha yoðun (1,5-2 kcal/ml) formlar
sývý kýsýtlamasý gerektiðinde yararlý olabilir, ancak bu ürünler yüksek ozmolariteden
dolayý ishal ve tüpün týkanmasý gibi <span class=GramE>komplikasyonlara</span>
neden olabilir. Ýshali önlemek için yüksek lif içerikli ürünler tercih
edilebilir. Böbrek yetmezliði, karaciðer yetmezliði, diabetes mellitus ve
akciðer hastalýðý varlýðýnda kullanýlabilecek özel ürünler mevcuttur. Bu özel
ürünlerin kullanýmý mutlak endike deðildir. Pek çok hastada standart ürünlerle
de gerekli beslenme tedavisi yapýlabilir. Böbrek yetmezliðinde düþük proteinli,
düþük elektrolitli ve kalorisi yüksek ürünler tercih edilebilir. Karaciðer
yetmezliðinde hepatik ensefalopati riskini arttýrmamak için özel aminoasitleri
içeren formlar tercih edilebilir. Akciðer hastalýðý olanlarda karbondioksit
üretimini azaltmak için yüksek yaðlý formlar kullanýlabilir. Sindirim sistemi
fonksiyon bozukluðu olanlarda karbonhidratlar ve proteinler oligosakkarit ve
aminoasit gibi yapýtaþlarý þeklinde verilerek emilim ve sindirim
kolaylaþtýrýlabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:14.0pt;line-height:150%;
background:white'><span style='mso-spacerun:yes'> </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Sonuç
olarak malnütrisyon nörolojik hastalýðý olan yaþlýlarda sýk görülür ve<span
style='color:black'> kas atrofisi (ekstremite/solunum), basý yaralarý, du&#776;þmeler,
osteoporoz, infeksiyon riski ve sað kalýmda azalma gibi birçok olumsuz duruma</span>
neden olabilir. Yaþlýda beslenme durumunu olumsuz etkileyen birçok faktör
vardýr. Malnütrisyonun ilk aþamada tanýnmasý büyük önem arz etmektedir. Her
hasta mutlaka malnütrisyon açýsýndan deðerlendirilmeli ve yeterli beslenemeyen
hastaya hýzla gerekli önerilerde bulunulmalýdýr. Ýhtiyaç halinde uygun beslenme
yolu seçilerek beslenme ürünleri ile beslenme desteði vakit kaybetmeden
baþlanmalýdýr. <b style='mso-bidi-font-weight:normal'><span style='color:black'><o:p></o:p></span></b></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%'><span style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>Sarkopeni</span></b><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Sarkopeni
yaþlanma ile birlikte ilerleyici kas kitle ve fonksiyon kaybýdýr. Nörolojik
hastalýklarda yaþam kalitesini bozan önemli bir iþlevsel kayýp sebebidir.
Sarkopeni, düþme, kýrýklar fiziksel kýsýtlýlýk ve mortalite gibi olumsuz sonuçlarda
artmaya neden olabilen ilerleyici ve jeneralize iskelet kasý rahatsýzlýðýdýr.
Klinik pratikte en sýk kullanýlan sarkopeni taný <span class=GramE>kriterleri</span>
EWGSOP (<span style='background:white'>European Working Group on Sarcopenia in
Older People) </span>kriterleridir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Sarkopeni
riski olan hastalar, düþen, yürüme hýzý yavaþ olan, sandalyeden kalkmakta
zorlanan, kilo kaybý/kas erimesi olan hastalardýr. Formal bir risk
deðerlendirmesi için SARC-F testi kullanýlabilir. SAR?-F testi pozitif saptanan
veya sarkopeni klinik þüphesi olanlarda sarkopeni varlýðýný saptamak için kas
gücü deðerlendirilmelidir. Kas gücünü saptamak için el dinamometresi ile elin
kavrama gücünün deðerlendirilmesi önerilir. Kas gücü düþük olanlarda muhtemel
(probable) sarkopeni tanýsý konur. Bu olgularda sarkopeninin etyolojik tanýsý
ve tedavisine yönelik giriþimler baþlamalýdýr. Kas gücü düþük olanlarda
sarkopeni tanýsýný doðrulamak için ikinci basamakta kas miktarý ve/veya
kalitesi klinik pratikte DXA ve BÝA <span class=GramE>ile,</span> çalýþmalarda
ise DXA, BÝA, BT veya MRI ile deðerlendirilebilir. Kas kütlesi
deðerlendirilirken ölçülen kas kütlesinin boy, kilo veya VKÝne göre
düzeltilmesi gerekir. Düþük kas gücü, düþük kas miktarý/kalitesi olanlarda
sarkopeninin ciddiyetini saptamak için fiziksel performans
deðerlendirilmelidir. Fiziksel performans deðerlendirmesinde kullanýlan testler
arasýnda olaðan yürüme hýzý, kýsa fiziksel performans bataryasý (SPPB), 6
dakika yürüme testi ve merdiven týrmanma gücü testi sayýlabilir. Yürümenin
deðerlendirilmesinde sýklýkla 4 metre olaðan yürüme hýzý kullanýlýr. Düþük kas
gücü, düþük kas miktarý/kalitesi ve düþük fiziksel performans tespit
edildiðinde, sarkopeni ciddi kabul edilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1;background:
yellow;mso-highlight:yellow;mso-shading:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Sarkopeni;
fiziksel kapasitede azalma, güçsüzlük, denge problemleri, hareket bozukluðu,
kýsýtlýlýk, solunum fonksiyonunda bozulma, kardiopulmoner performansta azalma,
olumsuz metabolik etkiler, baðýþýklýk sisteminde bozukluk, yaþam kalitesinde
azalma, kýrýlganlýk, günlük yaþam aktiviteleri ve enstrümental günlük yaþam
aktivitelerinde azalma, osteoporoz, düþmeler, hastane yatýþ süresinde uzama ve
ölümle iliþkilidir.<span style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Sarkopeni
etyolojisinde en önemli risk faktörleri mobilizasyonun azalmasý ve
malnütrisyondur. Özellikle eklem, kas, sinir ve kemikleri etkileyen
hastalýklar, kronik <span class=GramE>dahili</span> hastalýklar (karaciðer
yetersizliði, kalp yetersizliði, böbrek yetersizliði, solunum sistemi
problemleri, kanser, tüberküloz gibi kronik infeksiyonlar, bað dokusu
hastalýklarý), demans, depresyon, aðrý varlýðý, sosyoekonomik yoksunluk ve
bunun gibi durumlar baþlýca sarkopeni risk faktörleridir. Yaþlanma ile testosteron,
östrojen ve büyüme hormonu azalýr, bunlar da sarkopeni oluþumuna katkýda
bulunur. Kadýn cinsiyet, düþük doðum aðýrlýðý, alkol, sigara kullanýmý ve
kalýtsal özellikler sarkopeni için diðer risk faktörleridir. Sarkopeninin kesin
bir tedavisi yoktur fakat bazý önerilerle ve giriþimlerle mevcut sarkopeniyi
iyileþtirmek ve ilerlemesini önlemek mümkündür. Sarkopeninin önlenmesi ve
tedavisinde baþlýca egzersiz, yeterli beslenme ve bazý besinsel destekler
önerilmektedir. Sarkopeni açýsýndan risk altýnda olan bireylerin erken
tanýnmasý ve önlem alýnmasý düzeltilebilir risk faktörlerinin ortadan
kaldýrýlmasý oldukça önemlidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Egzersiz
sarkopeni tedavisinin temelini oluþturmaktadýr. Egzersiz mutlaka yeterli
beslenme ile kombine edilmelidir. Egzersiz çeþitleri arasýnda direnç
egzersizleri, hem kas kütlesi hem de kas fonksiyonlarýný iyileþtirmek için
güvenli ve en etkili yöntemdir. Direnç egzersizleri ile kas yapýmýnda olumlu
etkileri olduðu bilinen testosteron ve büyüme hormonu gibi anabolizan
hormonlarýn seviyesi artar. Yaþlýlarda direnç egzersizleri olarak duvarý itme,
sandalyeden kalkma, lastik germe, hafif aðýrlýklar kaldýrma yapýlabilir. Esneme
ve germe egzersizleri, hareket açýklýðýnýn idamesini saðlayarak; denge
egzersizleri ise dengeyi iyileþtirerek yaþlýlarda fonksiyonellikte olumlu
etkilere neden olur. En ideal egzersiz programý direnç, esneme, germe, denge ve
aerobik egzersizlerin <span class=GramE>kombinasyonu</span> ile olacaktýr.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:black;mso-themecolor:
text1'><a href="http://www.itfnoroloji.org/geriyatri/Sarkopeni.pdf">Ýstanbul
Týp Fakültesi Geriyatri Bilim Dalý tarafýndan oluþturulan sarkopeni egzersizi
broþürünü buradan indirebilirsiniz.</a><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Beslenme
desteði sarkopeni tedavisinin önemli bir parçasýdýr. Yaþlanmayla birlikte kas
yýkýmýnýn artmasý, eþlik eden hastalýklar ve bu hastalýklarýn alevlenme
dönemleri yaþlýda protein ihtiyacýný arttýrmaktadýr. Güncel klavuzlarda
yaþlýlarda proteinin 1-1,5g/kg/gün alýnmasýnýn daha uygun olduðu ifade
edilmektedir. Diyetteki proteinin miktarý ve 3 öðünde dengeli olarak alýnýyor
olmasýnýn yaný sýra kalitesi ve tüketim zamaný da önemlidir. Bazý elementer
proteinlerin kas üzerine daha etkili olduðu bilinmektedir. Özellikle lösin ve
metaboliti olan beta-hidroksi-metilbutirat (HMB)ýn kas üzerinde yapýmý uyarýcý
etkiye sahip olduðu bilinmektedir. HMB, kas kütlesi ve fonksiyonunda düzelme
saðlamaktadýr. Protein alýmýndan en etkili faydanýn saðlanmasý için egzersiz
sonrasý ilk saatte alýnmasý önerilmektedir. Ayrýca egzersiz sonrasý erken ve
yeterli proteinin yaný sýra yeterli karbonhidrat alýmý da saðlanmalýdýr. </span><span
style='font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>D
vitamini kas-iskelet sistemi saðlýðý için önemli bir besin öðesidir. </span><span
style='font-family:"Tahoma","sans-serif";color:#212121'>Düþük D vitamini
seviyeleri, düþük kas gücü ile iliþkili bulunmuþtur. D vitamininin düþük
seviyeli kiþilerde replasmaný, kas gücü ve iþlevini arttýrýr ve düþmeleri
azaltýr.<span style='mso-spacerun:yes'>  </span>Vitamin D replasmaný
mortalitede azalma ile iliþkilidir.</span><span style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> </span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'><o:p></o:p></span></p>

<pre style='text-align:justify;line-height:150%;background:white'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>Büyüme hormonu, testosteron ve östrojen kas fonksiyonu ve kütlesini etkileyebilen hormonlardýr. Testosteron tedavisinin sadece laboratuvar olarak testosteron eksikliði tanýsý kesinleþmiþ ve klinik bulgularý olan yaþlýlara uygulanmasý önerilir. Testosteronun kas kütlesinde artýþa neden olduðu bilinmektedir kas fonksiyonu ve performansý üzerine olumlu etkisi olabilir. Fakat bunun yaný sýra önemli yan etkilere (kardiovasküler risk artýþý, polisitemi, uyku apnesi, prostat büyümesi/prostat kanseri, karaciðer toksisitesi, ödem, jinekomasti gibi) neden olabileceði unutulmamalýdýr. </span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><span style='mso-spacerun:yes'> </span><o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%;background:white'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></pre><pre style='text-align:
justify;line-height:150%;background:white'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'>Sonuç olarak sarkopeni yaþlýlarda sýklýkla karþýmýza çýkan;</span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:black;mso-themecolor:text1'> fiziksel kapasitede, fonksiyonel kapasitede, kardiopulmoner performansta ve yaþam kalitesinde azalma, kýrýlganlýk, hastane yatýþ süresinde uzama ve ölümle iliþkili bir geriatrik <span
class=GramE>sendromdur</span>. Sarkopeni açýsýndan riskli olabilecek hastalar bu yönden deðerlendirilmeli ve gerekli tedbirler alýnmalýdýr. </span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121;background:white'>Sarkopeni tedavisinde ve önlenmesinde multimodal tedavi yaklaþýmýnýn bir parçasý olarak dengeli protein, enerji ve D vitamini alýmý, özellikle düzenli egzersizle birlikte kullanýldýðýnda yararlý olabilir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%;background:white'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Times New Roman","serif";color:#212121;background:white'><o:p>&nbsp;</o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>Düþmeler<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Düþmeler,
yaþlý <span class=GramE>popülasyonda</span> sýklýkla karþýmýza çýkan, ancak
yaþlanmanýn kaçýnýlmaz bir sonucu gibi görülmemesi gereken týbbi ve ekonomik
sonuçlarý açýsýndan önemli bir halk saðlýðý sorunudur. Mortalite ve morbidite
artýþýnýn yaný sýra, uzun süreli immobilizasyon ve buna baðlý <span
class=GramE>komplikasyonlara</span> neden olmaktadýr. Düþmeye baðlý geliþen
yaralanma ve kýrýklarýn yaný sýra kiþide geliþen düþme korkusu; hareketliliði
olumsuz yönde etkileyerek fonksiyonel kayýp, baðýmsýzlýkta azalma, depresyon ve
sosyal <span class=GramE>izolasyona</span> neden olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Yaþlý
<span class=GramE>popülasyonda</span> yaþýn ilerlemesi ve artan fiziksel
özürlülük ile düþme insidansý ve ciddiyeti artar. Toplumda yaþayan 65 yaþ
üzerindeki bireylerin %30-40ý her yýl düþer.<sup> </sup>Seksen yaþ ve üzeri
için bu oran yaklaþýk %50ye yükselmiþtir. Uzun süreli bakým evinde kalan
bireylerin %50si her yýl düþer ve düþme öyküsü olanlarýn yaklaþýk %60ý daha
sonra tekrar düþecektir. Demans, nöropatik ve miyopatik hastalýklar gibi
nörolojik hastalýklarýn çoðu düþmeler için baðýmsýz risk faktörüdür ve bu
nedenle nörolojik hastalýðý olan yaþlýlarda düþme oldukça sýktýr.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><sup><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></sup></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Düþmelerin
%10-15i büyük yaralanmalara neden olurken %37-56sý hafif yaralanmalarla
sonuçlanýr. Atmýþ beþ yaþ ve üzeri yaþtaki kiþilerde yaralanma ile ilgili hastaneye
yatýþlarýn baþlýca nedenidir ve bu yaþ grubundaki acil baþvurularýn %14ünü ve
hastaneye kabullerinin %4ünü oluþturmaktadýr. Yaþlý hastalarla ilgilenen
klinisyenler, düþmeleri rutin olarak sorgulamalý, düþme riskini deðerlendirmeli
ve altta yatan deðiþtirilebilir risk faktörleri varsa düzeltmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Düþme Risk Faktörleri<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:10.0pt;text-align:justify;line-height:
150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Yaþlýlarda
düþme nedenleri araþtýrýldýðýnda ilk sýrada çevresel faktörler nedeniyle
yaþanan kazalar (%30-50), ikinci sýrada ise denge ve yürüyüþ bozukluklarý
(%10-25) gelmektedir. Denge ve normal yürüme birçok sistemin birlikte
çalýþmasýyla saðlanýr. Görme fonksiyonu (görme keskinliði, derinlik algýlama, <span
class=GramE>kontrast</span> duyarlýlýðý, karanlýða uyum) iç kulakta bulunan
denge sistemi, yüzeyel ve derin duyu, eklemlerin serbest hareketi, kas gücü ile
kas koordinasyonu denge ve yürümeyi etkileyen baþlýca faktörlerdir. Denge ve
normal yürümede etkili olan bu sistemlerin hepsinde yaþlanmayla birlikte bazý
deðiþiklikler olur. <span class=GramE>Denge problemi olmayan ve normal yürüyen
bir yaþlýda dahi, araya giren ateþli bir hastalýk, ishal, kusma, aþýrý terleme,
diüretik kullanýmý gibi nedenlerle meydana gelen dehidratasyon, yeni ortaya
çýkan aritmi, ani tansiyon deðiþiklikleri, uyku bozukluklarý (gece sýk sýk
uyanma, uykuya dalmada ve/veya sürdürmede güçlük, toplam uyku süresinde
kýsalma, gün içinde kýsa süreli uyuklamalar, sürekli uykuya meyilli olma), yeni
baþlanan veya pozolojisi deðiþtirilen ilaç veya bir çevre deðiþikliði ardýndan
düþme olabilir. </span>Baþlýca düþme risk faktörleri aþaðýda özetlenmiþtir.<sup><span
style='color:red'><o:p></o:p></span></sup></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Yaþlý
bireylerde meydana gelen düþmeler çoðunlukla birden fazla nedenden
kaynaklanmaktadýr.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Psikososyal ve demografik
faktörler:</span></u><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'> ileri yaþ, kadýn cinsiyet, yalnýz yaþamak,
inaktivite, düþme <span class=GramE>hikayesi</span><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Medikal faktörler</span></u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>:
inme, Parkinson hastalýðý, kognitif bozukluklar, inkontinans, akut hastalýklar,
vestibüler bozukluklar, artrit, ayak problemleri, baþ dönmesi, senkop,
ortostatik hipotansiyon, D vitamin eksikliði, depresyon<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Ýlaçlar:</span></u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
Antihipertansifler, psikoaktif ilaçlar, nonsteroidal anti-inflamatuar ilaçlar
ve 4den fazla ilaç kullanýmý <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Denge ve mobilite
faktörleri</span></u><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'>: Denge kaybý, duruþ ve mobilite bozukluðu<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Duyusal ve nöromüsküler
faktörler:</span></u><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'> Görme bozukluðu, görme alaný kaybý,
vestibüler fonksiyonlarda azalma, kas güçsüzlüðü, azalmýþ periferik duyu <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Nöropsikolojik faktörler</span></u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>:
Depresyon, kognitif bozukluklar, düþme korkusu<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Çevresel faktörler:</span></u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
Uygun olmayan gözlükler, evde meydana gelebilecek tehlikeler, dýþ tehlikeler<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Düþme riskini tarama<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Basit
kullanýmý kolay bir tarama, yaþlýlarda son yýldaki düþme anamnezini alýp, denge
ve hareketlilik durumlarýný deðerlendirmektir. Daha önceki düþmeler ertesi yýl
tekrar düþme yönündeki en güçlü prediktörlerden biridir<b style='mso-bidi-font-weight:
normal'>.</b> Tüm yaþlý bireylere (veya bakýcýlarýna), özellikle nörolojik
hastalýðý olanlarda düþme riski fazla olduðu için, en az yýlda bir; düþme,
düþme sýklýðý, yürüyüþ veya denge bozukluðu sorulmalýdýr. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Deðerlendirme<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Tekrarlayan
düþmeleri olan, yürüyüþ ve denge ile ilgili sorunlarý olan, düþme sebebiyle
medikal yardým isteyen ve acile baþvuran yaþlý bireyler için multifaktöryel
düþme deðerlendirmesi yapýlmalýdýr. Deðerlendirmede düþme ile ilgili ayrýntýlý
anamnez alýnmalý ve ayrýntýlý fizik muayene yapýlmalýdýr. Fizik muayenede
yürüme hýzý, postür, kas gücü, postüral instabilite, Romberg ve kýsa fiziksel
performans testi, time up and go testi gibi postüral stabilite testleri
yapýlmalýdýr. Ayrýca görme keskinliði deðerlendirmesi, fýsýltý iþitme testi,
ekstremitelerin muayenesi yapýlmalýdýr. <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Tanýsal
Testler<o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'>Anemi, dehidratasyon ve otonom nöropatiyi
saptamak üzere tam kan sayýmý, BUN, kreatinin, glukoz düzeyleri bakýlmalýdýr.
Ayrýca D vitamini, vitamin B12 düzeyi deðerlendirilmelidir. Holter,
ekokardiyografi ve radyolojik incelemeler yalnýzca muayenedeki bulgular ve
anamnez neticesinde endike olduðu durumlarda önerilir.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Düþmeyi
Önleme Yaklaþýmlarý<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Düþmelerden korunmak için atýlmasý
gereken ilk adým risk faktörlerini belirlemek ve mümkün olanlarý
deðiþtirmektir. Yaþlýda düþmeye yol açan faktörlerin çoðunluðu düzeltilebilir risk
faktörleridir. Düþmeyi önleme ve sýklýðýný azaltmada; týbbi giriþimler,
çevresel düzenlemeler, eðitim ve egzersiz programlarý ve yardýmcý aletler
kullanýlabilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Düþmeyi önlemeye yönelik
yapýlabilecek basit týbbi giriþimler; <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='text-align:justify;line-height:150%;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Vitamin
B12 eksikliðini deðerlendirmek <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Sedatif
hipnotik ve santral etkili ilaçlarý kesmek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Servikal
spondilosis yönünde araþtýrma yapmak <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Ýlaç
sayýsýný azaltmak<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Çevresel
düzenlemeler yapmak<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Eðitim
programlarý, egzersizler (denge, kas kuvvetlendirme ve direnç egzersizleri, gözlem
altýnda egzersiz) uygulamak<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Yardýmcý
aletlerden (sert tabanlý uygun ölçüde ayakkabý, yürüteç, kalça koruyucularý)
klinik pratikte faydalanmak<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Postüral
hipotansiyonu araþtýrmak ve tespit edildiðinde etyolojisini araþtýrmak <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Ýlaçlar
gözden geçirmek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Aþýrý
tuz kýsýtlamasý yapanlarýn diyetini gözden geçirmek <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Yeterli
sývý alýnmasý saðlamak (2-2,5 lt/gün)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Beslenme
bozukluðu varsa tedavi etmek, az ve sýk yemek yemek ve alkolden kaçýnmasýný
söylemek, karbonhidratlý yiyeceklerden uzak durulmasýný önermek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Gerektiði
durumda, antihipertansif ilacýn dozu azaltýlmak veya baþka grup ilaçla
deðiþtirmek <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Yatak
baþýnýn yükseltilmesi, yataktan yavaþ kalkma, dorsifleksiyon egzersizleri, alt
ekstremite direnç egzersizlerini önermek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Varis
çorabý giyilmesi önermek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Bu
müdahaleler yetersiz kalýrsa midodrin ve fludrokortizon uygulanabilir<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>D
vitamini kullanýmýnýn yaþlýlarda düþme sayýsýný azalttýðý saptanmýþtýr. D
vitamini kullanýmýnýn kas gücünü arttýrarak bu azalmayý saðladýðý
düþünülmektedir. Özellikle kadýnlarda yararlý olduðu görülmüþtür. Osteoporozu
olan yaþlýlarda düþme sonrasý kýrýk riski arttýðý için osteoporoz tedavisi göz
ardý edilmemelidir. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='text-align:justify;line-height:150%;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><a
href="http://www.itfnoroloji.org/geriyatri/Dusme.pdf">Ýstanbul Týp Fakültesi Geriyatri
Bilim Dalý tarafýndan oluþturulan düþmeyi önleme için yapýlabilecekler
broþürünü buradan indirebilirsiniz.</a><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Sonuç olarak düþmeler yaþlýlarda sýk
görülür ve yýkýcý sonuçlara neden olabilir. Düþmelerin çoðu tek bir nedene
baðlý deðildir. Birbiriyle etkileþen birden çok faktörün sonucu olarak düþmeler
ortaya çýkmaktadýr. Düþmeleri önlemek için yapýlmasý gereken, risk
faktörlerinin belirlenmesi ve düzeltilebilir faktörlerin düzeltilmesidir.
Sonucu ne olursa olsun düþen ve sýk düþme tehlikesi yaþayan bir yaþlý mutlaka
bir doktor tarafýndan </span>deðerlendirilmeli, düþme nedenleri araþtýrýlmalý
ve düþmenin yaþlý üzerindeki etkileri analiz edilmelidir.<span
style='mso-spacerun:yes'>  </span><b style='mso-bidi-font-weight:normal'><o:p></o:p></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>Kýrýlganlýk<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Kýrýlganlýk, genellikle ileri yaþta ortaya çýkan düþkünlük durumunu
tanýmlar. Kýrýlgan bireylerin karakteristik özellikleri infeksiyon, uygunsuz
ilaç veya akut hastalýklar gibi stres faktörü varlýðýnda fiziksel ve kognitif
durumlarýnda ani ve dramatik deðiþiklik ve dekompansasyon riski taþýmalarýdýr.
Yaþlýlarda kýrýlganlýðýn olmasý alarm durumunu gösterir. Bu hastalar her türlü
dýþ etkene hassastýr. Kýrýlgan yaþlý her an düþme, kýsýtlýlýk, hastaneye yatýþ
ve ölüm riski altýndadýr. Kýrýlganlýk için standart bir taným yoktur.
Kýrýlganlýk yaþlýyý fonksiyonel açýdan daha baðýmlý hale getiren, düþme,
deliryum ve immobilite riskini arttýran, bakým evine yerleþme olasýlýðýný
artýran, hastane yatýþý ve mortalite artýþýna neden olan bir durumdur. </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'>Kýrýlganlýk tanýmlamasý ile ilgili tam bir
fikir birliði olmadýðý için kýrýlganlýk prevalansýný belirlemek zordur.
Kýrýlganlýk ile ilgili yapýlan epidemiyolojik çalýþmalarda farklý kýrýlganlýk
ölçekleri kullanýlmýþtýr. Bu nedenle kýrýlganlýk prevalansý kullanýlan ölçeðe
ve <span class=GramE>popülasyona</span> göre farklýlýk göstermektedir.
Kýrýlganlýkta rol oynayan faktörler iþtahsýzlýk, sarkopeni, immobilite,
ateroskleroz, denge bozukluðu, depresyon ve kognitif bozukluktur.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'><span style='mso-spacerun:yes'> </span><o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><span
style='mso-spacerun:yes'> </span>Kýrýlganlýk Tarama Araçlarý<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1'><o:p>&nbsp;</o:p></span></b></p>

<pre style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Kýrýlganlýðý deðerlendirmek için geçerliliði ve güvenilirliði kanýtlanmýþ birçok tarama aracý vardýr. En sýk kullanýlan taný aracý Fried kýrýlganlýk indeksidir. Kýrýlganlýk indeksine göre 5 <span
class=GramE>kriterden</span> 3 ve üzerinin olmasý kýrýlganlýk olarak tanýmlanýr. Bir veya ikisinin olmasý ise kýrýlganlýk-öncesini tanýmlar. Fried kýrýlganlýk indeksine göre tanýmlanan <span
class=GramE>kriterler</span> þunlardýr: <o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l14 level1 lfo16'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Kilo kaybý: son 1 yýlda &gt; 4,5 kg istemsiz kilo kaybý<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l14 level1 lfo16'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Güçsüzlük: cinsiyet veya boya uygun olarak dinamometre ile ölçülen kavrama kuvvetinin azalmýþ olmasý <o:p></o:p></span></pre>

<p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l14 level1 lfo16;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%;font-family:
Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Dayanma
gücü ve enerjinin azalmasý: yorgunlukla ilgili öz raporlamada dayanýksýzlýk ve
düþük enerji. CES-D ölçütünden iki soruyla tanýmlanan öz raporlamadaki
yorgunluk, kademeli egzersiz testinde ulaþýlan egzersiz seviyesiyle
iliþkilidir; bu VO2 maks ve onun iþaret ettiði kardiyovasküler hastalýðýn
habercisidir.</span></p>

<p class=Default style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l14 level1 lfo16;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:windowtext;
mso-fareast-language:TR'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
"Times New Roman";color:windowtext;background:white;mso-fareast-language:TR'>Yavaþlýk:
cinsiyet ve boya uygun olarak 4 metre yürüme süresinin uzun olmasý (&#8804; 159
cm &#8805;7 sn,&gt; 159 cm &#8805; 6 sn) <o:p></o:p></span></p>

<pre style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l14 level1 lfo16'><![if !supportLists]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Azalmýþ fiziksel aktivite: haftalýk kilo kalori harcamasýnýn düþük olmasý (erkek &lt; 383 kcal, kadýn &lt;270 kcal)<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Fried kýrýlganlýk indeksi en sýk kullanýlan ölçek olsa da klinik pratikte daha hýzlý ve uygulamasý daha kolay olan ve sýklýkla kullanýlan bir diðer tarama aracý ise FRAIL <span
class=GramE>skalasýdýr</span>. FRAIL <span class=GramE>skalasýna</span> göre 5 kriterden 3 veya üzerinin olmasý kýrýlgan, bir veya ikisinin olmasý kýrýlganlýk-öncesi olarak tanýmlanýr. FRAIL kýrýlganlýk <span
class=GramE>skalasýnýn</span> bileþenleri þunlardýr:<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Yorgunluk: son 4 haftanýn hepsinde veya çoðunda yorgunluk hissi olmasý<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Dayanýklýlýk: 10 adýmý dinlenmeden, tek baþýna ve yardýmsýz yürümekte zorluk çekmesi<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Ambulasyon: 200 metre veya üzeri mesafeyi tek baþýna, yardýmsýz ve güçlük çekmeden yürümekte zorluk çekilmesi<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Hastalýklar: 11 hastalýktan 5 ve üzerinde olmasý. Hipertansiyon, diyabet, kronik obstruktif akciðer hastalýðý, miyokard enfarktüsü, konjestif kalp yetersizliði, angina, astým, artrit, inme, böbrek hastalýðý, kanser (küçük deri kanserleri dýþýnda)<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Kilo kaybý: son 1 yýl içinde vücut aðýrlýðýnýn %5 veya üzerinin kaybedilmesi<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Diðer tarama aracý osteoporotik fraktürler çalýþmasý (SOF) indeksidir. SOF indeksine göre 3 bileþenden ikisinin olmasý kýrýlganlýk, bir bileþenin olmasý ise kýrýlganlýk-öncesi olarak tanýmlanýr. SOF indeksinin içerdiði <span
class=GramE>kriterler</span> þunlardýr:<o:p></o:p></span></pre><pre
style='margin-left:38.45pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l0 level1 lfo20'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Son 1 yýlda %5 veya üzeri kilo kaybýnýn olmasý<o:p></o:p></span></pre><pre
style='margin-left:38.45pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l0 level1 lfo20'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Kollarý kullanmadan 5 kez sandalyeden desteksiz kalkamama<o:p></o:p></span></pre><pre
style='margin-left:38.45pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l0 level1 lfo20'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Kendinizi enerji dolu hissediyor musunuz ? sorusuna olumsuz yanýt verilmesi<o:p></o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:black;mso-themecolor:
text1'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Kýrýlgan
Yaþlýnýn Tedavisi <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>Hastalar ve aileleriyle
birlikte hedef belirleme; kýrýlgan bireylere bakým saðlama, bireysel
öncelikleri belirleme, riskleri ve müdahalelerin faydalarýný tartma ve bakýmýn <span
class=GramE>agresifliðine</span> iliþkin kararlar vermede çok önemlidir. Zinde
yaþlýlar için, bilinen kronik hastalýklarý uygun þekilde tedavi edilmeli,
aralýklý akut hastalýklarý ve olaylarý yönetilmeli ve yaþa uygun tarama
önlemleri ve önleyici bakým saðlanmalýdýr. Orta derecede ve ciddi derecede
kýrýlgan bir hastada, genellikle hayati tehlikesi olmayan durumlar için <span
class=GramE>agresif</span> tarama veya müdahale komplikasyonlarla seyredebilir.
Giriþimsel iþlemler ya da hastanede yatýþlar, zaten büyük bir morbidite ve
mortalite riski taþýyan kýrýlgan bir yaþlýya gereksiz bir yük getirebilir ve
yaþam kalitesini azaltabilir. Bazý durumlarda bu tip hastalara <span
class=GramE>palyatif</span> bakým önerisi en uygun yaklaþým olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>Kýrýlgan yaþlýlarda koruyucu
yaklaþýmlar aþaðýdaki þekilde sýralanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Beslenme (<b>F</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>ood intake maintained)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Egzersiz (<b>R</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>esistance exercises)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Aterosklerozu önleme (<b>A</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>therosclerosis prevention)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Ýzolasyondan kaçýnma (<b>I</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>solation avoidance)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Aðrý tedavisi (<b>L</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>imit pain)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Egzersizler (<b>T</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>ai chi or other balance exercises)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Testosteron eksikliðinin tedavisi (<b>Y</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>early check for testosterone deficiency)<o:p></o:p></span></p>

<pre style='text-align:justify;line-height:150%'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>Kýrýlgan yaþlýlar genel yaþlý <span
class=GramE>popülasyonunda</span> en yüksek riskli bireylerdir ve bu grup
yaþlýlarýn kapsamlý geriatrik deðerlendirmeden (KGD) maksimum fayda elde
etmeleri beklenebilir. KGDnin genel hedefleri þunlardýr:<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l22 level1 lfo24;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><![if !supportLists]><span style='mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
color:#212121'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
font-family:"Tahoma","sans-serif";color:#212121'>Fiziksel ve kognitif
fonksiyonu iyileþtirmek<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l22 level1 lfo24;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><![if !supportLists]><span style='mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
color:#212121'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
font-family:"Tahoma","sans-serif";color:#212121'>Ýlaç reçetelenmesi ve ilaç
kullanýmýný optimize etmek <o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l22 level1 lfo24;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><![if !supportLists]><span style='mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
color:#212121'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
font-family:"Tahoma","sans-serif";color:#212121'>Bakým evine yerleþtirmeyi,
hastaneye yatýþý ve ölüm riskini azaltmak<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l22 level1 lfo24;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><![if !supportLists]><span style='mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
color:#212121'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
font-family:"Tahoma","sans-serif";color:#212121'>Hasta memnuniyetini arttýrmak<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>Sonuç olarak kýrýlgan yaþlýlar
çoðunlukla çoklu <span class=GramE>þikayetlerle</span> baþvurur; medikal
tedavilere ve týbbi giriþimlere toleranslarý düþüktür. Kýrýlganlýðýn ve bunun
doðuracaðý kötü sonuçlarýn farkýnda olmak, nedenlerini anlamak ve uygun tedavi
yaklaþýmlarý sunmak kýrýlgan yaþlý grubunda uygun bakým olanaklarýný saðlamak
açýsýndan büyük önem taþýr.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>Üriner Ýnkontinans <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>Üriner inkontinans (ÜÝ), miktarý ne
olursa olsun her türlü istemsiz idrar kaçýrma olarak tanýmlanmýþtýr</span><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>. </span></b><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'>ÜÝ yaþlanma ile birlikte sýklýðý artan önemli geriatrik <span
class=GramE>sendromlardan</span> birisidir. Nörolojik hastalýðý olan yaþlýlarda
sýklýkla karþýmýza çýkan bir sorundur. Yaþlýlar idrar kaçýrmayý sýklýkla <span
class=GramE>þikayet</span> olarak belirtmediði için klinisyenler tarafýndan
sorgulanmadýðý sürece taný konulamayabilir. Günlük pratiðimizde karþýlaþtýðýmýz
her yaþlýya üriner inkontinans sorgulamasý yapýlmalýdýr ve detaylandýrýlarak,
tipleri ve risk faktörleri sorulmalýdýr. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'>Toplumda yaþayan 60 yaþ ve üzeri yaþlýlarda prevalansý kadýnlarda %30-35
erkeklerde %20-25dir. Hastanede yatanlarda %40-70, bakýmevlerinde yaþayanlarda
ise %60 düzeyindedir. Yaþ ve bozulmuþ fonksiyonel durum, hem erkek hem de
kadýnlarda ÜÝ için baðýmsýz risk faktörleridir.</span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'>ÜÝ, multifaktöriyel etyolojik sebeplere baðlý olabilir. Ayný olguda
birden fazla faktör ÜÝ etyolojisinde rol oynayabilir. Ýnkontinans yaþlýlarda <span
class=GramE>kompleks</span> semptomlarla ortaya çýkabilen ve tedavi
edilebilmesi için multidisipliner yaklaþýma gerek duyulan geriatrik bir
sendromdur.</span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'> </span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Hastada <span
class=GramE>hijyen</span> kaybý, komþu bölgede selu&#776;lit ve basý yarasý
geliþimi, idrar yolu infeksiyonu, uyku bozukluklarý, seksüel disfonksiyon,
depresyon, sosyal izolasyon, kendine güven ve saygý yitimi, kýrýk ile
sonuçlanacak du&#776;þme riskinde artýþ, yaþam kalitesinin düþmesi ve bakým
evine yerleþtirilme riskinde artýþa neden olmasý açýsýndan yaþlýlar için önemli
bir sorundur.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>SVH,
demans, deliryum, normal basýnçlý hidrosefali, PH ve omurilik yaralanmasý gibi
birçok nörolojik hastalýkta ÜÝ görülmektedir. Aþaðýdaki tabloda nörolojik
hastalýklar ve inkontinansa neden olma mekanizmalarý bulunmaktadýr. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>Tablo 3.</span></b><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Baþlýca nörolojik hastalýklarda inkontinans ve nedenleri<o:p></o:p></span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='margin-left:36.0pt;border-collapse:collapse;border:none;mso-border-alt:
 solid windowtext .5pt;mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Serebrovasku&#776;ler
  hastalýklar ve demans <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l17 level1 lfo26;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Fonksiyonel
  ve kognitif bozukluk<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l17 level1 lfo26;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Üst motor
  nöron hasarý sonucunda detrusor aþýrý aktivitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Deliryum <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l16 level1 lfo28;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Fonksiyonel
  ve kognitif bozukluk<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Normal
  basýnçlý hidrosefali <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l11 level1 lfo30;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Frontal
  inhibitör merkezlerin inhibisyonu<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l11 level1 lfo30;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Fonksiyonel
  ve kognitif bozukluk<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Parkinson
  hastalýðý <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l6 level1 lfo32;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Pons <span
  class=GramE>iþeme</span> merkezine gelen inhibitör impulslarýn kaybý<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l6 level1 lfo32;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Fonksiyonel
  ve kognitif bozukluk<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l6 level1 lfo32;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Konstipasyonun
  tetiklediði retansiyon ve taþma tipi üriner inkontinans<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Omurilik
  yaralanmasý <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;mso-yfti-lastrow:yes'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l7 level1 lfo34;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Detrusor
  arefleksisi veya sfinkter dissinerjisi<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'>Geçici inkontinans<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>Üriner inkontinansý olan hasta hangi
prezentasyonla gelirse gelsin öncelikle geçici ve düzeltilebilir inkontinans
nedenleri açýsýndan araþtýrýlmalý ve tedavi edilmelidir. Geçici üriner
inkontinans nedenleri arasýnda ilaçlar, infeksiyonlar, atrofik vajinit-üretrit,
psikojenik hastalýklar (depresyon, deliryum), endokrin hastalýklar (diabetes
mellitus, hiperkalsemi), hareket kýsýtlýlýðý ve fekal impakt bulunmaktadýr.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'>Tablo 4.</span></b><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'> Ýlaçlar ve
inkontinans mekanizmalarý<o:p></o:p></span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 align=left
 width=635 style='width:476.1pt;border-collapse:collapse;border:none;
 mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:1024;mso-table-lspace:
 7.05pt;margin-left:4.8pt;mso-table-rspace:7.05pt;margin-right:4.8pt;
 mso-table-anchor-vertical:paragraph;mso-table-anchor-horizontal:margin;
 mso-table-left:left;mso-table-top:9.9pt;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><b style='mso-bidi-font-weight:
  normal'><span style='font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Ýlaçlar<o:p></o:p></span></b></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><b style='mso-bidi-font-weight:
  normal'><span style='font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Etkileri
  <o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Diüretikler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Poliüri, sýk idrara çýkma, sýkýþma<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Antikolinerjikler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Üriner retansiyon, taþma
  inkontinansý, </span><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'> </span>deliryum,
  sedasyon, konstipasyon, fekal týkaç</span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Psikotroplar<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>     
  </span>antidepresanlar<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>     
  </span>antipsikotikler<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>     
  </span>sedatif-hipnotikler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Antikolinerjik etkiler, sedasyon<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Antikolinerjik etkiler, rijidite,
  sedasyon, immobilite<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Sedasyon, deliryum, immobilite,
  üretral relaksasyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>GABAerjik
  ajanlar (gabapentin, pregabalin)</span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Noktu&#776;rnal
  poliu&#776;riye yol açan pedal ödem</span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Kolinesteraz inhibitörleri
  <span style='mso-tab-count:1'>  </span></span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Antimuskarinik
  etkileþimle üriner inkontinans</span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Narkotik analjezikler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Üriner retansiyon, gaita týkacý,
  sedasyon, deliryum<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Alfa adrenerjik blokerler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Üretral relaksasyon stres
  inkontinansýný kolaylaþtýrýr<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Alfa adrenerjik agonistler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Üriner retansiyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Anjiotensin dönüþtürücü enzim
  inhibitörleri<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Öksürük ile tetiklenen stres
  inkontinansý<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Beta adrenerjik agonistler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Nadiren üriner retansiyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Kalsiyum kanal blokerleri<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Bozulmuþ detrusor kontraktilitesi,
  üriner retansiyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Alkol<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Poliüri, sýkýþma, sedasyon, deliryum,
  immobilite<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Kafein<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Mesane iritasyonu<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;mso-yfti-lastrow:yes;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Nonsteroidal
  antiinflamatuar ilaçlar <span style='mso-tab-count:1'>         </span></span><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none;mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Noktu&#776;rnal
  poliu&#776;riye yol açan pedal ödem <o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>Kalýcý Üriner Ýnkontinans Tipleri<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Geçici
inkontinans nedenleri dýþlandýktan ve þartlar düzeltildikten sonra inkontinans
devam ediyorsa kalýcý inkontinans nedenleri du&#776;þu&#776;nu&#776;lmelidir.
Kalýcý inkontinans nedenlerini beþ baþlýk altýnda toplayabiliriz.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>1. Fonksiyonel Ýnkontinans:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Detrusor aktivitesi ile alt üriner sistem anatomi ve fonksiyonlarý
normal olmakla birlikte; demans, depresyon ve deliryum gibi kognitif ve
psikolojik problemleri olan kiþilerin kontinans yeteneðini organize edememesinden
ya da ortopedik problemler nedeni ile hareket yeteneði kýsýtlanmýþ kiþilerin
zamanýnda tuvalete gitme becerilerinin azalmasýndan kaynaklanmaktadýr.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>2. Stres Ýnkontinansý:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Yaþlýlarda ikinci en sýk karþýlaþýlan inkontinans tipidir. Pelvik taban
kaslarýnýn gevþemesi sonucu abdominal basýnç u&#776;retral sfinkter kapanma
basýncýný aþtýðýnda; öksu&#776;rme, gu&#776;lme, hapþýrma ve aðýr kaldýrma gibi
aktivitelerden sonra ku&#776;çu&#776;k hacimli idrar kaçýþý olmasýdýr. Genitou&#776;riner
atrofi veya prolapsus, <span class=GramE>travma</span>, geçmiþteki ürolojik
operasyonlar, morbid obezite, multiparite ve travmatik doðumlar stres
inkontinans geliþimi için birer risk faktöru&#776;du&#776;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>3. Sýkýþma Tipi Ýnkontinans:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Yaþlýlarda en sýk karþýlaþýlan ÜÝ tipidir. Detrusor aþýrý aktivitesine
baðlý olarak kontrol edilemeyen ani sýkýþma hissi ile idrar kaçýrýlmasýdýr.
Mesaneyi irrite eden taþ, infeksiyon, tu&#776;mör ve yabancý madde varlýðý ile
birlikte, fibrozis ya da yaþlanma ile detrusor kasýnýn kompliyansýnýn bozulmasý
sonucunda geliþebilir. Ayrýca birinci motor nöron bozukluklarý, inme, omurilik
hasarý, multipl skleroz ve PH aþýrý detrusor aktivitesine sebep olan
hastalýklardan bazýlarýdýr. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>4. Taþma Ýnkontinansý:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Bozulmuþ mesane duvar kontraksiyonu ya da sfinkterin gevþeme kusurundan
dolayý artan mesane volu&#776;mu&#776;nu&#776;n ve intravezikal basýncýn;
mekanik baský yaratarak su&#776;rekli bir idrar kaçýþýna neden olmasýdýr.
Prostat hipertrofisi, u&#776;retral striktu&#776;r, genitou&#776;riner organ
prolapsusu, antimuskarinik ilaçlar, nöropati ve omurilik yaralanmasý bu tip
inkontinansa neden olabilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>5. Mikst Ýnkontinans:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Stres tipi ve sýkýþma tipi inkontinansýn bir arada olduðu inkontinans
tipidir. Kadýnlarýn yarýsýndan fazlasýnda mikst tip inkontinans göru&#776;lu&#776;rken,
erkeklerde sýkýþma tipi inkontinans daha sýk göru&#776;lmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>Diðer bir birliktelik aþýrý
detrusor kas aktivitesine eþlik eden<b style='mso-bidi-font-weight:normal'> </b>bozulmuþ
mesane kontraktilitesidir. Özellikle kýrýlgan yaþlýlarda bu duruma eþlik eden
rezidü idrar varlýðýnda düzensiz mesane kontraksiyonlarý oluþur. Erkeklerde
daha sýk görülür. Klinik olarak sýkýþma, stres ve taþma inkontinansýný taklit
ettiði için taný konulmasý oldukça zor olup iyi sorgulanmasý ve
deðerlendirilmesi gerekmektedir. <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>Tedavi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif"'><span
style='mso-spacerun:yes'> </span><o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Tedavi yönetimi inkontinansýn tipine göre
ve hasta ve yakýnlarýnýn tercihine göre planlanmalýdýr. ÜÝ tedavisinde ilk adým
düzeltilebilir sebeplerin saptanmasý ve ortadan kaldýrýlmasý olmalýdýr.
Yaþlýlarda inkontinans geliþiminin genelde multifaktöryel olduðu ve üriner
sistem dýþýndaki sebeplerin ilk planda olabileceði unutulmamalýdýr. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Davranýþ
ve yaþam tarzý deðiþiklikleri tüm hastalarda öncelikli olarak önerilmesi
gereken tedavi seçeneðidir. Yaþam tarzý deðiþikliðinde </span><span
style='font-family:"Tahoma","sans-serif"'>sigara býrakma, inkontinans tipinden
baðýmsýz olarak tüm üriner inkontinansý olan hastalara önerilir. Diðer
öneriler; kafeini azaltmak, 2 lte kadar sývý alýmý (120ml öðünlerle alýnmasý),
obezlerde kilo verme, 2-3 saatte bir tuvalete gidilmesi, egzersiz, güçlü
kanýtlar olmasa da özellikle sýkýþma tipi ÜÝde önerilir.</span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
</span><span style='font-family:"Tahoma","sans-serif"'>Ýlaç tedavisi ile bu
önlemlerin birleþtirilmesinin tek baþýna ilaç tedavisine göre daha baþarýlý
(%58 vs %69) olduðu gösterilmiþtir. Davranýþsal müdahaleler pelvik taban kas
egzersizleri (kegel) ve mesane eðitimini içerir. Mesane eðitimi daha çok
sýkýþma tipi inkontinans tedavisinde ön plandadýr. Stres inkontinansý olan
kadýnlarda yalnýzca mesane <span class=GramE>volümü</span> yüksek olanlarda
etkilidir. Mesane eðitimi yöntemleri ve pelvik kas egzersizleri sýklýkla bir
arada kullanýlmaktadýr. Kegel egzersizleri 3 set halinde 10 kontraksiyon (10sn)
þeklinde uygulanýr. Stres ve urge inkontinansta uygulanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Farmakolojik tedavi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Stres
inkontinansýnýn</span></u><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'> tedavisinde </span><span
style='font-family:"Tahoma","sans-serif"'>ilaç tedavisi sýkýþma tipi
inkontinanstaki kadar etkin deðildir. Uygulanabilecek ilaç tedavileri arasýnda
imipramin, duloksetin, östrojen bulunmaktadýr. Ýmipramin, hem </span><span
style='font-family:Symbol;mso-ascii-font-family:Tahoma;mso-hansi-font-family:
Tahoma;mso-bidi-font-family:Tahoma;mso-char-type:symbol;mso-symbol-font-family:
Symbol'><span style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>a</span></span><span
style='font-family:"Tahoma","sans-serif"'> adrenarjik hem de antikolinerjik
etkisi nedeniyle özellikle kadýnlardaki mikst ÜÝde kullanýlmaktadýr. Fakat
yaþlýlarda antikolinerjik yan etkileri ve ortostatik hipotansiyon nedeniyle
kullanýlmasý önerilmemektedir. Duloksetin, serotonin ve noradrenalin geri alým
inhibitörüdür. Pudental siniri stimule ederek etki etmektedir. Yapýlan
çalýþmalarda stres ÜÝ sýklýðýnda belirgin bir iyileþmeye neden olduðu
saptanmýþtýr. Bulantý sýk görülen yan etkisidir. Östrojen yalnýzca internal
sfinkter yetersizliði bulunan kadýnlarda fayda saðlar. Vaginal östrojen
tedavisinin inkontinans <span class=GramE>semptomlarýnda</span> iyileþme
saðladýðýna dair bazý kanýtlar vardýr.<span style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<pre style='text-align:justify;line-height:150%'><u><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Sýkýþma tipi inkontinans</span></u><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'> tedavisinde amaç istemsiz kasýlmalarý azaltarak ya da bloke ederek sýkýþma <span
class=GramE>semptomlarýnýn</span> aralýklarýný uzatarak mesane kapasitesini iyileþtirmektir. Bu amaçla en çok kullanýlan ilaçlar antikolinerjiklerdir.<span style='mso-spacerun:yes'>  </span>Antikolinerjik ilaç seçimi dozaj sýklýðý, ilaç-ilaç etkileþimleri, yan etkiler, komorbiditeler ve maliyet göz önünde bulundurularak yapýlmalýdýr. Antikolinerjik ilaçlar aðýz kuruluðu, kabýzlýk, bulanýk görme, uyku hali, taþikardi ve kognitif fonksiyonlarda bozulmaya neden olabilir. Antikolinerjik ilaçlar gastrik retansiyon ve dar açýlý glokomda kontrendikedir. <o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Oksibutinin</span></i><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";background:white'>, en çok tercih edilen ilaçtýr. Oral ve transdermal uygulamasý mevcuttur. Oral formu aðýz ve göz kuruluðu, görme bozukluðu, kabýzlýk, baþaðrýsý, gastroözefageal reflü, idrar retansiyonu ve konfüzyon gibi yan etkilere neden olmaktadýr. Daha az yan etki için ilacýn baþlangýç dozu düþük tutulmalýdýr. Yan etki <span
class=GramE>profili</span> en düþük olan ilaç oksibutinin transdermal formudur.<span style='mso-spacerun:yes'>  </span>Yapýlan çalýþmalarda bu formun kognitif yan etkisinin plasebo ile eþ olduðu, aðýz kuruluðu ve konstipasyon yan etkisinin de diðer üriner antikolinerjiklerden daha düþük olduðu gösterilmiþtir. Oksibutinin kullanýmýnda mutlak kontrendikasyonlar obstrüktif üropati ve dar açýlý glokom, rölatif kontrendikasyon ise kardiyak aritmilerdir. <i
style='mso-bidi-font-style:normal'>Tolterodin</i>, oksibutin ile benzer etkilere sahip olmasýna raðmen yan etkiler daha azdýr. Renal ve hepatik sorunu olan hastalarda klirens deðiþeceði için doz düþürülmelidir. <i
style='mso-bidi-font-style:normal'>Trospiyum</i>, santral sinir sistemi yan etkisi olmayan antimuskarinik bir ilaçtýr. Absorbsiyonun tam olmasý için aç karnýna alýnmalýdýr. Kreatin klirensi 30 ml/dakdan düþük olanlarda günlük tek doz önerilmektedir. Polifarmasiye uygunluðu, yan etki sýklýðýnýn azlýðý ve etkinliði nedeniyle geriatrik olgularda iyi bir seçenektir. Yapýlan çalýþmalarda kognitif sürece herhangi bir olumsuz etkisi olmadýðý gösterilmiþtir. <i
style='mso-bidi-font-style:normal'>Propiverin</i>, antikolinerjik ajan olmasýnýn yaný sýra kalsiyum kanal <span
class=GramE>blokajý</span> ve D1-D2 blokajý da yapar. Dopamin blokaji yaparak parkinsonizme yol açabileceðinden yaþlýlarda kullanýlýrken dikkat edilmelidir. <i
style='mso-bidi-font-style:normal'>Darifenasin</i>, M3 selektif muskarinik reseptör <span
class=GramE>antagonistidir</span>. Oral yoldan baþlangýç dozu günde 7,5 mg tek dozdur en erken 2 hafta sonra 15mga çýkarýlabilir. Kognitif fonksiyonlara olumsuz etkisi yoktur. Kardiyak açýdan güvenlidir. <i
style='mso-bidi-font-style:normal'>Solifenasin</i>, önerilen günlük doz 5 mgdýr, gerekli durumlarda 10 mga çýkarýlabilir. Aðýz kuruluðu konstipasyon yan etkileri tolterodine göre daha fazladýr.<span style='mso-spacerun:yes'>  </span><o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Taþma tipi üriner inkontinansta BPHa
baðlý hafif obstrüksiyon durumunda </span><span style='font-size:10.0pt;
mso-bidi-font-size:8.0pt;line-height:150%;font-family:Symbol;mso-ascii-font-family:
Tahoma;mso-hansi-font-family:Tahoma;mso-bidi-font-family:Tahoma;background:
white;mso-char-type:symbol;mso-symbol-font-family:Symbol'><span
style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>a</span></span><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>-adrenerjik blokerler faydalýdýr. <i
style='mso-bidi-font-style:normal'>Prazosin, terazosin, doksazosin ve
tamsulosin</i>, trigon ve prostat düz kaslarýnda relaksasyona neden olarak
mesane boþalmasýný kolaylaþtýrýr. <i style='mso-bidi-font-style:normal'>Doksazosin</i>,
etki süresi en uzun ve yan etkileri en hafif olan etkin maddedir. Postural
hipotansiyon, kardiyovasküler, dermatolojik, solunum ve genitoüriner etkiler
nedeniyle geriatrik olgular takip edilmelidir. <i style='mso-bidi-font-style:
normal'>Prazosin</i>, esas olarak antihipertansif olarak kullanýlmaktadýr,
fakat tolerans geliþmesi nedeniyle seyrek kullanýlýr. <i style='mso-bidi-font-style:
normal'>Tamsulosin</i>, prostat bezinde bulunan </span><span style='font-size:
10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:Symbol;mso-ascii-font-family:
Tahoma;mso-hansi-font-family:Tahoma;mso-bidi-font-family:Tahoma;background:
white;mso-char-type:symbol;mso-symbol-font-family:Symbol'><span
style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>a</span></span><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>-adrenerjik reseptörler üzerine etki
gösterdiði için diðerlerine göre daha <span class=GramE>spesifiktir</span>, bu
nedenle hipotansif etkisi azdýr. Aç alýnmasý önerilir. <i style='mso-bidi-font-style:
normal'>Terazosin</i>, için geriatrik olgularda postural hipotansif etkisi
nedeniyle doz ayarý önerilmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Sonuç olarak yaþlý hastalarda ÜÝ sýk
görülür, ilerleyen yaþla birlikte artar, taný konulmaz ise birçok <span
class=GramE>komplikasyona</span> neden olur. ÜÝ hasta ve yakýnlarýnýn hayat
kalitesinde düþmeye, mortalitede artýþa, morbidite ve maliyette ciddi artýþa
neden olmaktadýr. Bu nedenle </span><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:black'>günlük
pratiðimizde karþýlaþtýðýmýz her yaþlýda ÜÝ sorgulanmalý, tipleri, risk
faktörleri belirlenmeli ve uygun davranýþ ve medikal tedaviler önerilmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Konstipasyon<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Kabýzlýk nörolojik hastalýklarda sýk görülen bir belirti ve <span
class=GramE>komplikasyondur</span>; erken tedavi edilmezse ve relapslarýn
önlenememesi durumunda hasta için ciddi sorun yaratabilir</span><span
style='font-family:"Tahoma","sans-serif";color:#212121;background:white'>.
Serebrovasküler hastalýklarý olanlarda prevalansý %30 ile %60 arasýnda
deðiþmekte ve inme sonrasý hastalarýn %55'inde yeni baþlangýçlý kabýzlýk
görülmektedir. PHde kabýzlýk, hastalarýn %50'sinden fazlasýnda meydana
geldiðine inanýlan en sýk görülen non-motor bulgulardan biridir.</span><span
style='font-family:"Tahoma","sans-serif"'> </span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Roma
IV <span class=GramE>kriterlerine</span> göre, fonksiyonel kabýzlýk, aþaðýdaki
özelliklerin herhangi ikisinin olmasý olarak tanýmlanýr: zorlama, topaklý sert
dýþký, tam boþalmama hissi, dijital manevralar kullanýmý, anorektal týkanýklýk
hissi veya baðýrsak hareketlerinin %25'inde azalma ile týkanýklýk ve dýþký
frekansýnda azalma (haftada üç baðýrsak hareketinden daha az). Tanýdan 6 ay
önce yukarýdaki <span class=GramE>semptomlar</span> baþlamýþ ve son 3 aydýr
devam ediyor olmalýdýr. </span><span style='font-family:"Tahoma","sans-serif";
color:#212121;background:white'>Yaþlý eriþkinlerde kabýzlýk fonksiyonel kronik
kabýzlýða baðlý veya diðer etyolojik faktörlere sekonder olabilir.</span><span
style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif";color:#212121;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif";color:#212121;background:white'>Primer
kolorektal disfonksiyon üç örtüþen alt tipten oluþur: yavaþ geçiþ kabýzlýðý,
dissinerjik defekasyon ve kabýzlýk ile birlikte iritabl baðýrsak <span
class=GramE>sendromu</span>. Sekonder kabýzlýk nedenleri kapsamlý bir öykü ve
fizik muayene ile takip edilmeli ve tanýsal testler yapýlmalýdýr.</span><span
style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'>Kronik fonksiyonel kabýzlýk tedavisinde ilk
adým yaþam tarzý ve diyet deðiþikliðidir. Genellikle 20 ila 25 g/günlük bir lif
alýmý tavsiye edilir.</span><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'> </span><span style='font-family:"Tahoma","sans-serif";
color:#212121;background:white'>Kronik kabýzlýðý olan, diyet ve yaþam tarzý
deðiþikliklerine cevap vermeyen yaþlý hastalarda fekal týkaç varlýðý dýþlanarak
lif desteði veya polietilen glikol baþlanmasý önerilmektedir.</span><span
style='font-family:"Tahoma","sans-serif"'> </span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Yaþlý
yetiþkinlerde laksatif kullanýmý, hastanýn öyküsü, komorbiditeleri, ilaç
etkileþimleri ve yan etkilerine göre bireyselleþtirilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
12.0pt;line-height:150%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
10.0pt;font-family:"Tahoma","sans-serif";text-transform:uppercase'>Nörolojik
hastalýklarýn tedavisinde kullanýlan ilaçlarýnýn sebep olabileceði <span
class=GramE>DAHÝLÝ</span> yan etkilerin ve ilaç-ilaç etkileþimlerinin yönetimi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Yaþlý hastalar eþlik eden komorbidite
yükü nedeniyle genellikle çok sayýda ilaç kullanýrlar. Ülkemizde grubumuz
tarafýndan bildirilen üniversite geriatri polikliniðine baþvuran hastalarýn ilk
baþvuruda kullandýklarý ortalama ilaç sayýsý 4,8dir. Öte yandan yaþlanmayla
iliþkili fizyolojik deðiþiklikler, eþlik eden hastalýklara baðlý geliþen
problemler nedeniyle yaþlýlar ilaçlarla iliþkili yan etkilere daha duyarlýdýr.
Uygunsuz ilaç kullanýmý yaþlýlarda kognitif bozukluk, deliryum, malnütrisyon,
ÜÝ, düþme, yaþam kalitesinde düþme, bakým ihtiyacýnda artýþ, hospitalizasyon ve
ölüm ile iliþkilidir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Bu nedenle tüm dünyada yaþlýlarda
uygunsuz ilaç kullanýmý ve polifarmasinin engellemesine yönelik stratejiler
geliþtirilmektedir. Bu baðlamda Akademik Geriatri Derneði Akýlcý Ýlaç Çalýþma
Grubu önderliðinde Türkiyede alanýnda uzman ve yaþlý hasta klinik pratiðinde
deneyimli öðretim üyelerinin geniþ katýlýmý ile Türkiye Yaþlýda Uygunsuz Ýlaç
Kullaným Kriterleri (Turkish Inappropriate Medication Use in the Elderly)-(TIME
Kriterleri) oluþturulmuþtur. Ýlaçlarýn etkili olduðu sistemler esas alýnarak
oluþturulan <span class=GramE>kriterler</span>, temel olarak yaþlýda
kullanýlmasý genelde veya bazý durumlarda uygun olmayan ancak klinik pratikte
sýklýkla yanlýþ kullanýlan ilaçlar (TIME - to STOP) ve yaþlýda kullanýlmasý
genelde veya bazý durumlarda özellikle yararlý olan ancak klinik pratikte
sýklýkla kullanýlmayan ilaçlardan (TIME -to START) oluþmaktadýr. Bu baðlamda
Ýstanbul Týp Fakültesi Nöroloji Anabilim Dalý Davranýþ Nörolojisi ve Hareket
Bozuklarý ve Beyin Damar Hastalýklarý birimleri ile Psikiyatri Anabilim Dalý
Geropsikiyatri biriminden öðretim üyelerinin katký verdikleri TIME-Merkezi Sinir
Sistemi Kriterleri oluþturulmuþtur. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Kolinesteraz inhibitörleri<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Artan yaþ ve deðiþen fizyoloji ile birlikte geriatrik
olgularda komorbid durumlar ve geriatrik <span class=GramE>sendromlar</span>
artmaktadýr. Demans tedavisinde kullanýlan ilaçlar bazý komorbid durumlarda etkileþebilmektedir
ve önemli yan etkilere neden olabilirler. Bu durumlarýn bilinmesi ve tedaviye
baþlamadan önce ve tedavi sýrasýnda her zaman göz önünde bulundurulmasý
yaþlýnýn tedavisinin düzenlenmesinde ciddi önem arz etmektedir.<span
style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Gastrointestinal sistem
(GÝS):</span></u></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> Bulantý, kusma, ishal,
karýn aðrýsý, þiþkinlik, dispepsi, iþtahsýzlýk ve kilo kaybý en sýk görülen
gastrointestinal sistem yan etkileridir. Düþük kilolu (&lt;55 kg) olgularda,
düþük VKÝ olanlarda ve kadýnlarda GÝS yan etkileri daha fazla görülmektedir.
GÝS yan etkileri doz baðýmlý olup birkaç hafta içerisinde tolerans geliþir ve
azalarak kaybolur. Eðer kaybolmazsa veya hasta tolere edemezse bir önceki doza
dönülebilir. Ýlaçlara yaklaþýk 3 günden fazla ara verilmiþse en düþük dozdan
baþlamak gerekir, aksi halde GÝS yan etkileri abartýlý þekilde ortaya çýkabilir
ve tedaviye uyum bozulabilir. GÝS toleransý en iyi rivastigmin bant&gt;
donepezil &gt;galantamin &gt;oral rivastigmin (en kötü) þeklindedir.
Asetilkolinesteraz (AChE) inhibitörleri artmýþ kolinerjik aktiviteye baðlý
olarak gastrik asit sekresyonunu arttýrabilir. Özellikle gastrik ülser <span
class=GramE>hikayesi</span> olanlarda ve nonsteroid anti inflamatuar ilaç
kullananlarda aþikar veya gizli gastrointestinal kanama semptomlarý açýsýndan
takip edilmelidir. Rivastigmin ile ilgili klinik çalýþmalar, peptik ülser
hastalýðý veya gastrointestinal kanama insidansýnda plaseboya göre anlamlý bir
artýþ göstermemiþtir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Kardiyovasküler
sistem:</span></u></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> <span style='color:black'>Kardiyak
ileti bozukluklarý, senkop, hipotansiyon, hipertansiyon, periferik ödem
kardiyovasküler sistem yan etkileridir. Kolinerjik aktivitedeki artýþ kalp
üzerinde vagotonik etkilere neden olabilir. </span>Persistan bradikardi
(&lt;50/dk), 2. veya 3. derece kalp bloðu veya açýklanamayan senkop olan
hastalarda, QTc uzamasý olan hastalarda (kadýn 470msn, erkekte 450 msn)
asetilkolinesteraz inhibitörü kullanýmý uygun deðildir (kalp iletim defekti,
senkop, yaralanma riski). Kalp tepe atýmý 50-60/dk olan ve asemptomatik olan
hastalarda, AChE inhibitörleri baþlanabilir. Tedavi baþlangýcý veya doz
artýrýmýndan 1 hafta sonra kalp tepe atýmý ve <span class=GramE>semptom</span>
açýsýndan kontrol edilmelidir. Eþ zamanlý hýz kýsýtlayýcý ilaç alanlarda kalp
tepe atýmý &lt;50/dk deðilse ve <span class=GramE>semptom</span> yok ise,
dikkatle kullanýlabilir. Sol dal bloðu ve atrial fibrilasyon olanlarda dikkatli
kullanýlmalýdýr, hastalar takip edilmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Pulmoner sistem:</span></u></i><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'> Kronik obstrüktif akciðer hastalýðý veya astým gibi
hastalýðý olanlarda dikkatli kullanýlmalýdýr. Bronkospazm þiddetini
arttýrabilir.<sup><span style='color:red'> </span></sup>Ayrýca AChE
inhibitörleri pnömoni riskini arttýrabilir özellikle ilk baþlandýðý dönemde
tedavi baþlanmadan ve tedavi sýrasýnda bu riskler göz önünde bulundurulmalýdýr.
<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Santral sinir
sistemi:</span></u></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> Baþaðrýsý, baþ dönmesi,
sersemlik hissi, düþme, <span class=GramE>ajitasyon</span>, agresyon,
anksiyete, depresyon, halüsinasyonlar ve delüzyonlara neden olabilir. Ýnsomni,
somnolans, REM uyku davranýþ bozukluðu gibi uyku bozukluklarý görülebilir.
Epilepsi öyküsü olanlarda dikkatli kullanýlmalýdýr. Kolinomimetikler jeneralize
epileptik nöbetlere neden olabilirler.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Üriner sistem</span></u></i><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>:</span></i><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'> Yapýlan çalýþmalarda gözlenmemesine raðmen kolinerjik
aktivite artýþý nedeniyle üriner obstrüksiyona neden olabilirler. Benign
prostat hiperplazisi veya mesane çýkýþ yolu obstrüksiyonu olanlarda dikkatli
kullanýlmalýdýr. Üriner inkontinansta artýþa neden olabilir. Ýdrar yolu
infeksiyonu ve sýk idrara çýkma gibi yan etkiler görülebilir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Nöromüsküler ve
kas-iskelet sistemi:</span></u></i><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> Kas kramplarý
(donepezilde daha belirgin), artrit, artralji, sýrt aðrýsý, yorgunluk,
güçsüzlük, tremor, kreatinin kinaz enzim yüksekliði ve paresteziye neden
olabilir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ýlaç-ilaç
etkileþimleri<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Antikolinerjikler ve AChE inhibitörleri arasýnda
karþýlýklý etkileþim vardýr. Birbirlerinin etkisini azaltabilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Beta-blokerlerle, özellikle kardiyoselektif beta
blokerlerle (atenolol <span class=GramE>dahil</span>) birlikte AChE
inhibitörleri kullanýldýðýnda, senkop ile sonuçlanan ilave bradikardi etkileri
oluþabilir AChE inhibitörlerinin beta-blokerler ile birlikte kullanýlmasý
tavsiye edilmez. Steroidler AChE inhibitörlerinin yan etkilerini artýrabilir,
kas güçsüzlüðünü artýrabilir. Anestezide süksinil kolin tipi kas gevþemesini
artýrabilir. Donepezil: <span class=GramE>Karaciðer<span
style='mso-spacerun:yes'>  </span>ve</span> böbrek yetersizliðinde doz
ayarlamasý önerilmez. Rivastigmin: Karaciðer ve böbrek yetersizliðinde doz
ayarlamasý önerilmez. Galantamin: Ciddi karaciðer ve böbrek yetersizliðinde
kullanýlmasý önerilmez. Child B ve orta düzey böbrek yetersizliðinde maksimum
16 mg önerilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Memantin<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Kolinerjik ajanlardan daha az yan etkiye sahiptir, hatta
plaseboya benzer.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Kardiovasküler
sistem:</span></u></i><u><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> </span></u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Hipertansiyon, kalp yetmezliði, senkop, SVH ve TÝA
önemli yan etkilerdir. Bu vasküler yan etkilerden dolayý kardiyovasküler
hastalýk <span class=GramE>hikayesi</span> olanlarda dikkatli kullanmak
gerekir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Santral sinir
sistemi:</span></u></i><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> </span></u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Sersemlik en sýk görülen yan etkidir. Baþ dönmesi, baþaðrýsý,
<span class=GramE>halüsinasyonlar</span>, somnolans, yorgunluk, agresyon,
ataksi ve vertigo görülebilir. Ajitasyon özellikle Lewy cisimcikli demans
hastalarýnda görülebilir. Epilepsi öyküsü olanlarda dikkatli kullanýlmalýdýr,
nöbet riskini arttýrabilir. <u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Nöromüsküler ve kas
iskelet sistemi:</span></u></i><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> </span></u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Sýrt aðrýsý ve hipokineziye neden olabilir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Gastrointestinal
sistem:</span></u></i><u><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> </span></u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Konstipasyon, kusma, kilo kaybý görülebilecek yan
etkilerdir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Respiratuvar sistem</span></u></i><u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>: </span></u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Öksürük, dispne
görülebilir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Göz hastalýklarý: </span></u></i><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Katarakt ve konjuktivit oluþumunu attýrdýðý için
oftalmik hastalýðý olanlarda dikkatli kullanmak ve belirli aralýklarla göz
muayenesi yaptýrmak gerekir. <u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ýlaç etkileþimi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Karbonik anhidraz inhibitörleri ve sodyum bikarbonat
memantinin ekskresyonunu azaltabilir. Trimetoprim memantinin yan etkilerini
arttýrabilir. Özellikle miyoklonus ve deliryum riski artabilir. Her iki ilaç da
birbirlerinin serum düzeyini arttýrabilir. Hafif -orta böbrek yetmezliðinde doz
ayarlamasý önerilmez. Glomerüler filtrasyon hýzý 30mL/dknýn altýnda olanlarda
5mg baþlanmasý ve en az bir hafta kullanýmdan sonra en yüksek doz olan 10 mga
çýkarýlmasý önerilir. Klirens alkali idrar ile anlamlý olarak azalýr. (ilaç,
diyet)<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Ciddi hepatik yetmezlik durumunda dikkatli kullanýlmalý,
doz artýþý daha yavaþ yapýlmalýdýr, bölünmüþ dozlarda verilebilir ve yakýn
takip edilmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Antipsikotik Ýlaçlarýn <span
class=GramE>Dahili</span> Yan Etkileri<o:p></o:p></span></b></p>

<pre style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><span
style='mso-tab-count:1'>               </span><o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Ýkinci kuþak antipsikotiklerle iliþkili ortak yan etkiler arasýnda kilo alýmý ve ilgili metabolik etkiler, hipotansiyon, sedasyon, antikolinerjik <span
class=GramE>semptomlar</span>, hiperprolaktinemi, ekstrapiramidal semptomlar (EPS), kardiyak etkiler, kardiyomiyopatiler, kataraktlar ve cinsel iþlev bozukluðu yer alýr. Nadir fakat ciddi yan etkiler, tardiv diskinezi, nöroleptik malign <span
class=GramE>sendrom</span>, nöbetler, agranülositoz, hipersensitivite reaksiyonlarý ve özellikle demans ile iliþkili psikozu olan yaþlý eriþkin hastalarda tüm bu nedenlere baðlý mortalite riski artmaktadýr.<o:p></o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Metabolik yan
etkiler: </span></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Ýkinci kuþak
antipsikotiklerin yaygýn yan etkisi kilo artýþý ve bununla iliþkili metabolik
etkileridir. <span style='color:#212121'>Kilo alýmý, diyabet ve dislipidemi, i</span>kinci
kuþak antipsikotiklerle <span style='color:#212121'>iliþkili metabolik <span
class=GramE>sendromun</span> bileþenleridir. Bu <span class=GramE>semptomlara</span>
neden olan mekanizma tamamen açýk deðildir, ancak bu ilaçlarla hem iþtah artýþý
hem de deðiþen metabolik kontrol için kanýt vardýr.</span><u><o:p></o:p></u></span></p>

<pre style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Klozapin ve olanzapin, diðer antipsikotiklere göre anlamlý derecede daha yüksek risk taþýmakta iken, aripiprazol, lurasidon, pimavanserin ve ziprasidon en düþük riskle iliþkilidir. Bu <span
class=GramE>semptomlarýn</span> potansiyel morbiditesi nedeniyle antipsikotik ilaçlarý alan hastalarda rutin kýsa ve uzun süreli kilo, bel çevresi, kan basýncý, açlýk glikozu ve lipit profili takibi önerilmektedir.<o:p></o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Endokrin yan etkiler:</span></i><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'> </span><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast'>Hiperprolaktinemi</span><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>: <span style='color:#212121'>Prolaktin yükselmesi-
Erkeklerde ve kadýnlarda prolaktin salgýlanmasý, büyük ölçüde, hipofiz bezi
üzerindeki tromroinfundibular dopaminin inhibitör etkisi ile kontrol edilir.
Hipofiz dopamin reseptörlerinin direkt <span class=GramE>blokajý</span>,
prolaktin sekresyonuna izin verir. Artmýþ prolaktin düzeylerinin klinik
sonuçlarý arasýnda jinekomasti, galaktore, adet düzensizlikleri, cinsel iþlev
bozukluðu ve infertilite, kýsmen azaltýlmýþ östrojen ve testosteron düzeylerine
aracýlýk eder. </span><u><o:p></o:p></u></span></p>

<pre style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ýkinci kuþak antipsikotikler <span
style='color:#212121'>arasýnda risperidon ve paliperidon en yüksek oranda prolaktin ve daha az derecede asenapin, olanzapin ve ziprasidon ile iliþkilidir. Aripiprazol, brekspiprazol, kariprazin, klozapin, iloperidon, lurasidon, pimavanserin ve ketiyapin ile prolaktin düzeylerinde çok az deðiþiklik olur veya hiç deðiþmez. Risperidon ayrýca, diðer antipsikotiklerle karþýlaþtýrýldýðýnda belirgin bir þekilde artmýþ hipofiz adenomu (1000 hasta için 0,5) ile iliþkili bulunmuþtur.<o:p></o:p></span></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Risperidon ve paliperidon kullanan hastalarýn 12 hafta boyunca her vizitte ve daha sonra yýlda bir cinsel fonksiyon deðiþikliði ve anormal laktasyon varlýðý sorgulanmalýdýr. Hastada cinsel iþlev bozukluðu veya galaktore bulgularý geliþirse, serum prolaktin seviyesi ölçülmelidir. <o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></i></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Seksüel yan etkiler:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> <span
style='color:#212121'>Cinsel aktivitenin tüm aþamalarýnda disfonksiyon (libido, uyarýlma ve orgazm) antipsikotik tedavide sýk görülür. 2011 yýlýnda yapýlan bir meta-analizde i</span>kinci kuþak antipsikotiklerden<span
style='color:#212121'>; klozapin, olanzapin veya risperidon alan hastalarýn yüzde 40 ila 60'ýnda cinsel yan etkiler görüldüðü ve aripiprazol, ketiyapin ve ziprasidonda yüzdelerin daha düþük olduðunu ancak yine de %16 ila 27 arasýnda anlamlý oranlarda yaþandýðý saptanmýþtýr. </span>Daha yakýn zamanda yapýlan bir çalýþmada p<span
style='color:#212121'>aliperidon ve risperidon alan hastalarýn %60 ila 70'inde cinsel yan etki yaþandýðý, olanzapin, ketiyapin ve ziprasidon alanlarýn %50 ila 60'ýnda, klozapin alanlarýn %50'den azýnda ve aripiprazol alanlarýn %16 ila 27sinde cinsel yan etkiler yaþandýðý tespit edilmiþtir. Klinisyenler, baþlangýçta ve en az yýlda bir kez cinsel iþlevsellik ile ilgili zorluklarý özellikle sormalýdýrlar.</span><u><o:p></o:p></u></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Kardiyovasküler yan
etkiler:</span></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> <span style='color:#212121'>QTc
intervali uzamasý ve ani ölüm kardiyak yan etkilerdir. </span>Ýkinci kuþak
antipsikotiklerin <span style='color:#212121'>birçoðunun QT aralýðýnýn
uzamasýna neden olduðu bilinmektedir.<span style='mso-spacerun:yes'>  </span>QT
uzamasý, torsade de pointes ve potansiyel olarak ölümcül aritmilerin riskini
artýrýr. Antipsikotik tedavi sýrasýnda 500 msn'den daha fazla bir düzeltilmiþ
QT aralýðý (QTc) veya QTc'de 60 msn veya daha fazla bir artýþ torsade de
pointes için anlamlý risk olduðunu göstermektedir.</span><sup><span
style='color:red'> </span></sup><span style='color:#212121'>Spesifik ikinci
kuþak antipsikotikler ve QT intervali uzamasý ile iliþkileri þunlardýr:</span><u><o:p></o:p></u></span></p>

<pre style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Ýloperidon</span></i><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> </span></b><span style='mso-bidi-font-size:8.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:#212121'>ve<b style='mso-bidi-font-weight:
normal'> </b><i style='mso-bidi-font-style:normal'>ziprasidon</i><b
style='mso-bidi-font-weight:normal'>,</b> diðer ikinci kuþak antipsikotiklere göre önerilen en yüksek oral dozlarda QTc'de sýrasýyla 9 msn ve 10 msn ortalama artýþ ile daha fazla QT uzamasý riskine sahiptir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Her iki ilaç da doðrudan kardiyak ölümle iliþkilendirilmemiþtir, ancak önceden var olan QT uzamasý, diðer kardiyovasküler hastalýklar, hipokalemi veya QT aralýðýný uzatan diðer ilaçlarla eþzamanlý kullanýmý gibi diðer risk faktörleri ile birlikte vakalar bildirilmiþtir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Baþlamadan önce bilinen risk faktörleri olan hastalarda ilacýn sürekli bir tedavi düzeyine ulaþmasý ve yeni bir kardiyak <span
class=GramE>semptomun</span> ortaya çýkmasý durumunda bir elektrokardiyogram (EKG) önerilmektedir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Ketiyapin,</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> doz aþýmý vakalarýnda QT uzamasý ile iliþkilidir ve<i
style='mso-bidi-font-style:normal'> asenapin</i><b style='mso-bidi-font-weight:
normal'> </b>ve<i style='mso-bidi-font-style:normal'> paliperidon </i>gibi kardiyak riski olan hastalarda kullanýmý ile ilgili bir uyarý ifadesi taþýmaktadýr.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Olanzapin</span></i><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'> </span></b><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>ve<b style='mso-bidi-font-weight:normal'> </b><i
style='mso-bidi-font-style:normal'>risperidonun</i> her biri hafif QT uzamasý ile iliþkilidir, ancak bu konuya özel bir dikkat gösterilmemiþtir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Lurasidon, aripiprazol,</span></i><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'> </span></b><i
style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>brekspiprazol ve kariprazin,</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> kardiyak aritmilere en az neden olan ilaçlardýr, ancak hiçbir kardiyak risk faktörü olmayan bir hastada aripiprazol ile QT uzamasý ve kardiyak ölüm bildirilmiþtir. <o:p></o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Antipsikotik kullanan ve kardiyak risk faktörü olmayan
hastalarda rutin EKG izlemi önerilmez. <span style='color:#212121'>QT aralýðýný
uzattýðý bilinen diðer ilaçlarý alan kiþiler de <span class=GramE>dahil</span>
olmak üzere, kardiyak risk faktörleri olan hastalarda hiçbiri tamamen risksiz
deðildir ve uygun dikkat gösterilmelidir.</span><o:p></o:p></span></p>

<pre style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Miyokardit ve kardiyomiyopati:</span></i><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'> <i
style='mso-bidi-font-style:normal'>Klozapin,</i> çoðu kez ilk birkaç hafta veya ay içinde ölümcül olan miyokardit ve kardiyomiyopati vakalarý ile iliþkilendirilmiþtir.</span><sup><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:red'> </span></sup><span style='mso-bidi-font-size:8.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:#212121'>Klozapin ile yýllýk miyokardit insidansý geniþ bir aralýkta bildirilmiþtir ve ölüm oraný yüzde 0,01-0,1 arasýndadýr.<u><o:p></o:p></u></span></pre><pre
style='line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='line-height:150%'><i
style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Ketiapin, risperidon ve ziprasidon</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> ile nadir olarak miyokardit ve kardiyomiyopati bildirilmiþtir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Ortostatik hipotansiyon:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> Alfa-adrenerjik <span class=GramE>blokaj</span>, ikinci kuþak antipsikotiklerin neden olduðu ortostatik hipotansiyonun olasý mekanizmasýdýr. Genellikle, ortostatik taþikardi eþlik eder, her ikisi de en sýk ilaçlara maruz kalmanýn ilk birkaç gününde veya doz artýrýldýðýnda görülür. Kan basýncý ve kalp atým hýzýndaki deðiþiklikler en sýk klozapin, iloperidon, ketiyapin ve paliperidon ve daha az sýklýkla olanzapin, risperidon ve ziprasidon ile görülür. Nadiren aripiprazol, asenapin, brekspiprazol, kariprazin, lurasidon ve pimavanserin ile ortaya çýkarlar. Semptomlar genellikle benign ve kendini sýnýrlayýcýdýr, ancak bazý durumlarda, tek bir günlük dozun iki veya üç küçük doza bölünmesi, doz titrasyon hýzýnýn yavaþlatýlmasý veya ilaçta deðiþiklik yapýlmasý gerekebilir. </span><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'>Kan basýncý ve kalp atým hýzý tedavi baþlangýcýnda, 3. ayda ve daha sonra yýlda bir takip edilmelidir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black'>Hematolojik yan etkiler:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'> Klozapin ile nötropeni, lökopeni ve agranülositoz belgelenmiþtir. </span><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Bu ölümcül durum, tedavinin ilk birkaç ayýnda, önceden düþük hücre sayýmý olan hastalarda ve daha önce ilaca baðlý kan diskrazisi olanlarda daha sýk görülür. Klozapin ile tedavi edilen hastalarýn yaklaþýk %3'ünde lökositoz ve yaklaþýk %1'inde agranülositoz geliþebilir. Klozapin kullanan hastalarýn nötropeni için rutin olarak izlenmesi ve ciddi vakalarda ilacýn kesilmesini gerekir. Diðer antipsikotikler ile bu bulgular daha düþük oranlarda görülür.<span style='mso-spacerun:yes'>  </span>Lökositoz ve nötropeni risperidon alan hastalarýn %4'ünde, paliperidon veya ketiapin alanlarýn %2'sinde ve diðer ikinci kuþak antipsikotikleri alan hastalarýn %1'inden daha azýnda ortaya çýkmaktadýr. Þiddetli nötropeni veya agranülositoz vakalarý bildirilmiþtir ancak nadirdir. Diðer antipsikotikleri alan daha önceden ilaca baðlý lökositopenisi olan veya önceden düþük bir lökosit sayýmýna veya düþük nötrofil sayýmýna sahip olan hastalar için, tedavinin ilk birkaç ayýnda izleme yapýlmasý önerilmektedir. Spesifik bir takip aralýðý önerilmemesine raðmen, nötrofil sayýmýnýn bazalde, 1 -2 hafta sonra ve 3-6 ay sonra yapýlmasý makul yaklaþým olacaktýr. <u><o:p></o:p></u></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Antikolinerjik etkiler:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> Aðýz kuruluðu, konstipasyon, bulanýk görme veya üriner retansiyon izlenebilir. Klozapin kullanýmýnda ise aðýz kuruluðundan ziyade sialore görülür.<span style='mso-spacerun:yes'>  </span>Klozapin sekonder antipsikotikler içinde muskarinik reseptörler için en güçlü afiniteye sahiptir ve yan etkiler bu ilaçla en sýk ve þiddetlidir. Diðer sekonder antipsikotikler arasýnda olanzapin ve ketiyapin geri kalan ilaçlardan daha yüksek antikolinerjik problemlere sahiptir. Sýklýkla profilaktik ajanlar da dahil olmak üzere kabýzlýðýn <span
class=GramE>agresif</span> tedavisi, fekal impaksiyon veya baðýrsak perforasyonu gibi ciddi yan etkilerden kaçýnmak için gerekli olabilir. Antikolinerjik etki en fazla olandan en az olana sýrasýyla klozapin ve olanzapin, risperidon, ketiyapin ve haloperidoldur.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black'>Sedasyon:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> Klozapin ve ketiyapin ile hastalarýn yarýsýnda sedasyon ön plana çýkmaktadýr. Asenapin, lurasidon, olanzapin ve ziprasidon ile sedasyon %10 ila 25 <span
class=GramE>aralýðýnda</span> oranlara sahiptir. <u><o:p></o:p></u></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Aripiprazol, brekspiprazol, kariprazin, paliperidon, pimavanserin ve risperidon gibi diðer ilaçlar, hastalarýn %10'undan azýnda sedasyona neden olurlar. Aripiprazol ile hastalarýn %18'inde uykusuzluk rapor edilmiþ olup bu oran sersemlik için rapor edilen deðerin üç katýdýr.<span style='mso-spacerun:yes'>  </span>Antipsikotikler içinde sedatif etkisi en fazla olandan en az olana sýralandýðýnda ketiyapin, klozapin ve olanzapin, risperidon ve haloperidoldur.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Hastalar ilk birkaç tedavi dozu ile uyuþukluk konusunda uyarýlmalý ve ilk izlem ziyareti sýrasýnda yan etki hakkýnda sorular sorulmalýdýr. Tedavide erken dönemde sedasyon geçiren hastalara periyodik olarak tekrar sorulmalýdýr.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black'>Düþmeler:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'> </span><span style='mso-bidi-font-size:8.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>FDA</span><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'> (Food and drug administration)</span><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>, 2017'de antipsikotik ilaçlarýn uyku hali, postüral hipotansiyon ve/veya motor ve duyusal instabilite sonucu düþmelere ve kýrýklara neden olabileceði konusunda uyarýda bulunmuþtur. Bu etkileri þiddetlendirebilecek durumu olan ya da ilaç kullanan hastalar için, FDA antipsikotik tedavisi baþladýðýnda ve uzun süreli antipsikotiklere devam eden hastalarda tekrarlayan bir risk deðerlendirmesi yapýlmasýný önermiþtir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black'>Artmýþ mortalite riski:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'> </span><span style='mso-bidi-font-size:8.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>2005'ten beri FDA, ikinci kuþak antipsikotiklerin, demansla iliþkili psikozu olan yaþlý eriþkin hastalarýn tüm nedenlere baðlý ölümünde 1,6 ila 1,7 kat artýþla black box uyarýsýný gerektirdiðini belirtmiþtir. Bu hastalar arasýnda <span
class=GramE>spesifik</span> ölüm nedenleri kalp hastalýklarý (%25), SVH (%8), pulmoner hastalýk (%8), kanser (%7) ve diyabet (%3) idi. Yaþlý bunama hastalarý ile sýnýrlý büyük bir popülasyona dayalý kohort çalýþmasýnda, ikinci kuþak antipsikotiklerden aripiprazol, olanzapin, risperidon ve ziprasidon arasýnda hiçbir fark bulunmamýþ, fakat ketiyapin % 20 daha düþük bir risk oluþturmuþtur.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Steroidler<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Glukokortikoidlerin
yan etkileri hem doz hem de süreye baðlýdýr. Glukokortikoidlerin etkilerine glukokortikoid
reseptörleri aracýlýk eder ve bu ajanlarýn terapötik etkilerinde de rol oynayan
hem genomik hem de nongenomik mekanizmalardan kaynaklanýr.<span
style='mso-spacerun:yes'>  </span>Glukokortikoid reseptöründeki ve
glukokortikoid metabolizmasýndaki genetik polimorfizmler, gözlenen glukokortikoid
toksisitelerindeki heterojenliði açýklayabilir.</span><span style='font-size:
10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
<span style='color:#212121;background:white'>Glukokortikoidlerin birçok organ
sistemi üzerinde olumsuz etkileri vardýr.</span><span style='color:#212121'> <span
style='background:white'>Dermatolojik ve görünüm üzerine görülen yan etkiler;
purpura, ekimoz, ciltte incelme, kilo artýþý, Cushingoid görünüm, akne,
hirsutizm, </span>yüzde eritem ve strialardýr. Oftalmolojik yan etkiler
arasýnda posterior subkapsüler katarakt, yüksek göz içi basýncý/glokom ve
egzoftalmus bulunmaktadýr.</span> <span style='color:#212121'>Kardiyovasküler
sistem yan etkileri; sývý retansiyonu, hipertansiyon, prematüre arteroskleroz
ve aritmilerdir. </span><span style='mso-spacerun:yes'> </span><span
style='color:#212121'>Sindirim sistemi yan etkileri; gastrit, peptik ülser
hastalýðý, steatohepatit, visseral perforasyondur.</span> <span
style='color:#212121'>Kas iskelet sistemine ait yan etkiler osteoporoz,
avasküler nekroz ve miyopati olarak bildirilmiþtir.</span> <span
style='color:#212121'>Nöropsikiyatrik yan etkiler arasýnda öfori,
disfori/depresyon, uykusuzluk, akatizi, mani/psikoz, psödotümor serebri
bulunmaktadýr.</span> <span style='color:#212121'>Metabolik ve endokrin sisteme
ait görülebilecek yan etkiler hiperglisemi, hipotalamo-hipofiz-adrenal
yetmezliktir.</span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Artan infeksiyon
riski ölümcül sonuçlara varabilen yan etkidir.<span style='mso-spacerun:yes'> 
</span>HBsAg veya HBV DNA (+) olgularda kullanýmlarý HBV aktivasyonu nedeniyle
fulminan hepatitle sonuçlanabileceðinden, tedaviye baþlamadan önce HBsAg,
anti-HBs, anti-HBc IgG ve gerekli olgularda HBV DNA bakýlmalý ve gerekli
olgulara antiviral profilaksi baþlanmalýdýr. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
class=GramE><b style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;
mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";text-transform:
uppercase'>DAhiliyede</span></b></span><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
text-transform:uppercase'> sýk kullanýlan ilaçlarýn nörolojik hastalýklarýn
kliniði üzerine olan yan etkilerinin yönetimi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Hiperglisemi-hipoglisemi, hipoksi,
hiperkarbi, hipotansiyon-hipertansiyon, dehidratasyon, elektrolit
dengesizlikleri, metabolik asidoz-alkaloz, hipotiroidi-hipertiroidi, böbrek
yetersizliði, karaciðer yetersizliði, anemi, nütrisyonel eksiklikler gibi
sistemik veya metabolik bozukluklarýn normal nöronal iþlevi bozabileceði
bilinmektedir. Bu sistemik veya metabolik bozukluklara neden olabilecek
ilaçlar, mevcut nörolojik hastalýðýn kötüleþmesi durumunda mutlaka gözden
geçirilmeli, gerekli düzenlemeler yapýlmalý ve önlemler alýnmalýdýr.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;line-height:
150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><b
  style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Tablo 5. Nörolojik hastalýklarda klinik bozulmaya
  katkýda bulunabilecek-etkileyebilecek ilaçlar<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:54.2pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:54.2pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Glisemi
  düzeyini etkileyen ilaçlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l5 level1 lfo36'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Hipoglisemi: oral antidiyabetikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l5 level1 lfo36'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Hiperglisemi: steroidler<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:54.2pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:54.2pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kan
  basýncýný etkileyen ilaçlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l20 level1 lfo38'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Hipotansiyon: antihipertansifler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l20 level1 lfo38'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Hipertansiyon: steroid, siklosporin,<span
  style='mso-spacerun:yes'>  </span>-NSAÝ<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:54.2pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:54.2pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Elektrolitleri
  etkileyen ilaçlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l4 level1 lfo40'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Diüretikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l4 level1 lfo40'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'> </span>(ACEÝ/ARB)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:54.2pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:54.2pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Sývý
  durumunu etkileyen ilaçlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l1 level1 lfo42'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Diüretikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l1 level1 lfo42'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Steroidler, NSAÝ<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:72.65pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:72.65pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Karaciðer-böbrek
  toksisitesi yapabilen ilaçlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l9 level1 lfo44'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Statinler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l9 level1 lfo44'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>ACEÝ/ARB<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l9 level1 lfo44'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>NSAÝ<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Anemi
  yapabilen ilaçlar <o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  class=MsoSubtleEmphasis><span style='font-size:14.0pt;mso-bidi-font-size:
  12.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;font-style:normal;
  mso-bidi-font-style:italic'><span style='mso-list:Ignore'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>Metotreksat&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:major-fareast;
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'>&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  color:black;mso-themecolor:text1;font-style:normal;mso-bidi-font-style:italic'><o:p></o:p></span></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  class=MsoSubtleEmphasis><span style='font-size:14.0pt;mso-bidi-font-size:
  12.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;mso-fareast-language:
  EN-US;font-style:normal;mso-bidi-font-style:italic'><span style='mso-list:
  Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>Trimetoprim&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:major-fareast;
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'>&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'><o:p></o:p></span></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  class=MsoSubtleEmphasis><span style='font-size:14.0pt;mso-bidi-font-size:
  12.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;mso-fareast-language:
  EN-US;font-style:normal;mso-bidi-font-style:italic'><span style='mso-list:
  Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>Hidroksiüre&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:major-fareast;
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'>&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'><o:p></o:p></span></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  class=MsoSubtleEmphasis><span style='font-size:14.0pt;mso-bidi-font-size:
  12.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;mso-fareast-language:
  EN-US;font-style:normal;mso-bidi-font-style:italic'><span style='mso-list:
  Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>Zidovudin&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:major-fareast;
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'>&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'><o:p></o:p></span></span></p>
  <p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  style='font-size:14.0pt;mso-bidi-font-size:12.0pt;line-height:150%;
  font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
  style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>5-Florourasil</span></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>NSAÝ: nonsteroid antiinflamatuar ilaçlar, ACEÝ/ARB:
Anjiotensin dönüþtürücü enzim inhibitörleri/anjiotensin reseptör blokerleri<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
12.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
10.0pt;font-family:"Tahoma","sans-serif";text-transform:uppercase'>Nörolojik
Hastalýðý Olan Yaþlýdaki Sistemik Hastalýklarýn Yönetimi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif"'>Hipertansiyon
<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Hipertansif
olgularýn ¾ü 50 yaþ üstündedir. Altmýþ yaþ üstü bireylerde hipertansiyon
prevalansý %60-80 dir. </span><span style='font-family:"Tahoma","sans-serif"'>Nörolojik
hastalýðý olanlarda kan basýncý kontrolü oldukça önem arz etmektedir.
Hipertansiyonun inme için majör risk faktörü olduðu bilinmektedir. Öte yandan
inmeli hastalarda serebral hipoperfüzyon riski nedeniyle anlamlý
hipotansiyondan da kaçýnýlmalýdýr. Benzer þekilde hipertansiyon vasküler demans
için bir risk faktörüdür. Hipotansiyon veya hipertansiyon kaynaklý serebral
perfüzyondaki bozulma kognitif fonksiyonda bozulmaya neden olmaktadýr. Öte
yandan PHde veya otonom nöropatilerde otonom fonksiyonlardaki bozulma nedeni
ile hipertansiyon tedavisinin sýk <span class=GramE>komplikasyonlarýndan</span>
olan ortostatik hipotansiyon riski diðer hastalara göre daha fazladýr.<b
style='mso-bidi-font-weight:normal'> </b></span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Hipertansiyon tedavi
hedefleri ile ilgili son dönemde yeni güncellemeler yapýlmýþtýr. 2018 Avrupa
Kardiyoloji Derneði hipertansiyon taný ve tedavi kýlavuzunda 65-80 yaþ arasý
bireylerde diyabet, koroner arter hastalýðý ve kronik böbrek hastalýðýndan baðýmsýz
olarak &gt;140 /90mmHgnýn üzerinde (ofis tabanlý kan basýncý ölçümü ile), 80
yaþ üstünde ise 160/90 mmHgnýn üstünde tedavi baþlanmasý önerilir. Seksen yaþ
üzerinde hipertansiyon tedavisi iyi tolere ediliyor ise tansiyon düþürücü
tedavinin kesilmemesi önerilir. 2017 ACC/AHA (American Cardiology
Collage/American Heart Association) hipertansiyon kýlavuzuna göre 65 yaþ üstü
bireylerde hedef sistolik kan basýncý &lt;130 mmHg (ambulatuar kan basýncý
monitörizasyonu ile) olarak ifade edilmektedir Tüm diyabetiklerde <u>&gt;</u>130/80
mmHg ile ilaç tedavisi baþlanmasý önerilmektedir. Bu hedefler büyük ölçüde
zinde yaþlýlar için geçerlidir. Komorbidite yükü fazla olan veya sýnýrlý yaþam
süresi beklenen olgularda, klinik deðerlendirme/hasta tercihi ve takým
yaklaþýmý ile kan basýncý hedefleri bireyselleþtirilmelidir. Yaþlýda
hipertansiyon tedavisinde önemli sýnýrlama yapan sebepler ortostatik
hipotansiyon, postprandial hipotansiyon ve mental fonksiyonlarda kötüleþmedir. </span><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ortostatik
hipotansiyonu, kognitif yýkýmý, fonksiyonel kýsýtlýlýðý, düþük yaþam beklentisi
(&lt;2 yýl) veya düþme riski yüksek olan yaþlýlarda sýký kan basýncý kontrolü
(&lt;140/90 mmHg) uygun deðildir.</span><b style='mso-bidi-font-weight:normal'><span
style='font-family:"Tahoma","sans-serif"'> <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ortostatik
hipotansiyonu (sistolik kan basýncýnda <u>&gt;</u>20 mmHg düþüþ veya diastolik
kan basýncýnda <u>&gt;</u>10 mmHg düþüþ) olanlarda tüm antihipertansifler doz
azaltýmý açýsýndan deðerlendirilmelidir. Ortostatik hipotansiyon yönetiminde
sekonder faktörler dýþlanmalý ve öncelikli olarak non-farmakolojik yaklaþýmlar
uygulanmalýdýr. Bu yaklaþýmlarla cevap alýnamayan hastalarda ilaç tedavisi
denenebilir. <span style='color:black'><span style='mso-spacerun:yes'> </span></span><span
class=GramE><span style='color:black;mso-themecolor:text1'>Non-farmakolojik
yaklaþýmlar arasýnda ayaða yavaþ kalkmak, alt </span>ekstremite direnç
egzersizleri, varis çorabý giymek, yeterli sývý alýmý [22,5 L/gün], alkolden
kaçýnmak, az ve sýk yemek yemek, yeterli tuz alýmý [&gt;8g], karbonhidrattan
zengin yiyeceklerden uzak durmak, sýcak havada yoðun egzersizden kaçýnmak,
yatarken baþý 45 derece yüksekte tutmak bulunmaktadýr. </span>Ülkemiz için
özgün olarak geliþtirilen TIME ilaç kullanýmý <span class=GramE>kriterlerinde</span>
yaþlýlarda hipertansiyon tedavisi ile ilgili dikkat edilmesi gereken noktalar
vurgulanmýþtýr.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Hiperlipidemi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Belgelenmiþ aterosklerotik koroner
arter hastalýðý (geçirilmiþ akut koroner <span class=GramE>sendrom</span>,
koroner anjiyografide plak varlýðý), SVH (geçirilmiþ iskemik SVH/TÝA veya
intrakraniyal/ekstrakraniyal ateroskleroz varlýðý) veya periferik arter
hastalýðý olan hastalarda sekonder korunma amaçlý statin tedavisi baþlanmasý
önerilmektedir.<span style='mso-spacerun:yes'>  </span>Diabetes mellitus
varlýðýnda LDL düzeyi &gt;100 mg/dl olmasý durumunda, eþlik eden en az bir kardiyovasküler
hastalýk risk faktörü (hipertansiyon, ailede kardiyovasküler hastalýk öyküsü,
sigara kullanýmý, albüminüri gibi) varsa primer kardiyovasküler korunma için
statin tedavisi baþlanmasý güncel kýlavuzlarda önerilmektedir. Yaþam beklentisi
2 yýldan düþük olan hastalarda, terminal demansý olanlarda, 85 yaþ üstü
hastalarda statinden beklenen faydalaným düþüktür; statin yan etkileri
(miyopati, hepatik) daha fazladýr. Bu hastalarda statin kullanýmýna olgu
bazýnda, hasta/hasta yakýný bilgilendirmesi ile karar verilmelidir. </span><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ülkemiz
için özgün olarak geliþtirilen TIME ilaç kullanýmý <span class=GramE>kriterlerinde</span>
yaþlýlarda hiperlipidemi tedavisi ile ilgili dikkat edilmesi gereken noktalar
vurgulanmýþtýr.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Diabetes mellitus</span></b><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif";color:black'>Fonksiyonel, kognitif
kapasitesi normal ve yaþam beklentisi, tedaviden yararlanmayý saðlayacak ölçu&#776;de
uzun (örn. &gt;10 yýl) olan yaþlý hastalarda glisemik kontrol hedefleri, genç
diyabetliler gibidir. Bu hastalarda Hemoglobin A1C (HbA1c) &#8804;%7, açlýk ve
öðu&#776;n öncesi plazma glukozu 80-130 mg/dl, gece plazma glukozu 90-150 mg/dl
olarak hedeflenmelidir. Çoklu kronik hastalýðý olan, hafif-orta derecede
kognitif bozukluðu olan yaþlýlarda yaþam su&#776;resi kýsalmýþtýr. Bu grup
hastada HbA1c düzeyi %7,1 ila 8 arasýnda, açlýk ve öðu&#776;n öncesi plazma
glukozu 90-150, gece plazma glukozu 100-180 mg/dl olarak hedeflenmelidir.</span><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> </span></b><span
style='font-family:"Tahoma","sans-serif";color:black'>Komplikasyonlarý
ilerlemiþ, eþlik eden önemli saðlýk sorunlarý bulunan, yaþam beklentisi kýsa,
kýrýlgan ve fonksiyonel ya da kognitif kapasitesi sýnýrlý olan ileri yaþtaki
diyabetlilerde glisemik ve metabolik hedefler daha esnek tutulmalýdýr. Bu hastalar
için HbA1c &gt;%8,5 arasýnda ve açlýk veya preprandiyal plazma glukozu 100-180
mg/dl, gece plazma glukozu 110-200 mg/dl olmasý önerilmektedir. Bu grup
hastalarda hipoglisemiden korunma temel hedef olmalý ve tedavide karmaþýk
olmayan, uygulamasý kolay ve basit ilaçlar tercih edilmelidir. Özellikle insu&#776;lin
tedavisi gerektiren hastalarda insu&#776;line baþlanmadan önce kognitif
sorunlar deðerlendirilmelidir. </span><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Diyabet komplikasyonlarýnýn
fonksiyonel kapasiteyi sýnýrlayabileceði unutulmamalý ve <span class=GramE>komplikasyon</span>
taramalarý güncel yaklaþýmlara uygun olarak yapýlmalýdýr. Bununla beraber yaþam
beklentisi çok sýnýrlý olan hastalarda <span class=GramE>komplikasyon</span>
taramasý ve erken tedavisinden saðlanacak ek yararlarýn görülmesi mümkün
olamayacaðýndan tüm tarama programlarýnýn uygulanmasý gerekmeyebilir.</span><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Hipotiroidi-Hipertiroidi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Yaþlý
hastalarda tiroid hastalýklarý sýk görülmektedir ve tedavi edilmezse ciddi
sorunlara neden olabilmektedir. Yaþlýlarda tiroid hastalýklarýnýn taný ve
tedavisi, <span class=GramE>semptomlarýn</span> tipik olmamasý, normal
deðerlerin genç eriþkinlere göre farklýlýk göstermesi, komorbiditeler ve
tedavileri nedeniyle hastalýðýn seyrinin daha ciddi olmasý ve tedavisinin
zorlaþmasý gibi birçok faktör nedeniyle zor olabilmektedir. Yaþlýda
hipotiroidizm dikkat, hafýza, <span class=GramE>konsantrasyon</span> gibi
kognitif fonksiyonlarda bozulmaya neden olabilir. Ayrýca ciddi hipotiroidizm
depresyon ve demans þeklinde ortaya çýkabilir. Ötirodizmin saðlanmasý ile bu
bulgular genellikle normale döner. Yaþlý hastalar tiroid hormon fazlalýðýna
daha hassaslardýr bu nedenle düþük dozla baþlanýp doz ayarlamasý dikkatli
yapýlmalýdýr. Ýyatrojenik tirotoksikoz özellikle atrial fibrilasyon ve
osteoporotik kýrýklara neden olabileceði için hassas titrasyon önemlidir.
Yaþlýda TSH düzeylerinin 4-6 mIU/L tutulmasý önerilmektedir. Seksen yaþ
üzerindeki yaþlýlarda ise TSH hedef düzeyi daha yüksek düzeylerde olabilir
ancak TSH 10 mIU/Lyi geçmemelidir.</span><span style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Subklinik hipotiroidisi olan yaþlýlarda (TSH: 4-10 mIU/L;
sT4: N), tiroid hormonu replasman tedavisi ek yararý olmadýðý, atrial fibrilasyon
ve osteoporoz gibi potansiyel yan etki riski nedeniyle önerilmemektedir. Ayrýca
yetmiþ yaþ üzerinde subklinik hipotiroidide mortalite daha azdýr ve replasman
baþlanmasýnýn mortalite üzerinde ek faydasý yoktur. Yetmiþ yaþ üzerinde
subklinik hipotiroidide TSH &lt;10 mU/L ise takip ve 6 ay sonra TSH kontrolü
önerilmektedir. </span><span style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Hipertiroidik yaþlý bireylerin 2/3ünde genç eriþkinlere
benzer <span class=GramE>semptomlar</span> (tremor, anksiyete, çarpýntý, kilo
kaybý, sýcak intoleransý gibi sempatik hiperaktivite semptomlarý) görülürken
1/3ünde apatetik hipertiroidizm görülür. Bu hastalar baþlýca atrial
fibrilasyon ve kalp yetersizliði gibi kardiyak bulgular ve açýklanamayan kilo
kaybý ile baþvurabilirler. Hipertiroidi saptanan yaþlýlarda etyolojiyi
araþtýrmaya yönelik uygun tetkikler istenmeli ve kýsa zamanda tedavi
edilmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;color:#212121'>Kaynaklar: <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Cruz-Jentoft AJ, Bahat G,
Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer
AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing
Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2),
and the Extended Group for <span class=GramE>EWGSOP2 .</span> Sarcopenia:
revised European consensus on definition and diagnosis. Age Ageing. 2018 Oct
12. doi: <span class=GramE>10.1093</span>/ageing/afy169. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Burgos R, Bretón I,
Cereda E, Desport JC, Dziewas R, Genton L, Gomes F, Jésus P, Leischker A,
Muscaritoli M, Poulia KA, Preiser JC, Van der Marck M, Wirth R,Singer P,
Bischoff SC. ESPEN guideline clinical nutrition in neurology. Clin Nutr 2018;<span
class=GramE>37:354</span>-396. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Bauer J, Biolo G,
Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, Phillips S, Sieber C, Stehle
P, Teta D, Visvanathan R, Volpi E, Boirie Y. Evidence-based recommendations for
<span class=GramE>optimal</span> dietary protein intake in older people: a
position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;<span
class=GramE>14:542</span>-59 <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Inouye SK, Westendorp RG,
Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-22. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Chang JT, <span
class=GramE>Morton</span> SC, Rubenstein LZ, Mojica WA, Maglione M, Suttorp MJ,
Roth EA, Shekelle PG. Interventions for the prevention of falls in older
adults: systematic review and meta-analysis of randomised clinical trials. BMJ.
2004;328(7441):680<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Sternberg SA, Wershof
Schwartz A, Karunananthan S, Bergman H, Mark Clarfield A. The identification of
frailty: a systematic literature review. J Am Geriatr Soc. 2011;<span
class=GramE>59:2129</span>-38<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Gauthier S. Cholinergic
adverse effects of cholinesterase inhibitors in Alzheimer's disease:
epidemiology and management. Drugs Aging.2001;<span class=GramE>18:853</span>-62.
<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%;color:black;
mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%;color:black;
mso-themecolor:text1'>Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical
antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. <span
class=GramE>2009 ;360</span>:225-35<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%;color:black;
mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Volkert D, Beck AM,
Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, Kiesswetter E, Maggio M,
Raynaud-Simon A, Sieber CC, Sobotka L, van Asselt D, Wirth R, Bischoff SC.
ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr.
2018; pii: S0261-5614(18)30210-3. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><sup><span
style='color:red'><o:p>&nbsp;</o:p></span></sup></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
class=GramE><span style='font-size:10.0pt;line-height:150%;color:black'>Morley
JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, Doehner W, Fearon KC, Ferrucci
L, Hellerstein MK, Kalantar-Zadeh K, Lochs H, MacDonald N, Mulligan K,
Muscaritoli M, Ponikowski P, Posthauer ME, Rossi Fanelli F, Schambelan M,
Schols AM, Schuster MW, Anker SD; Society for Sarcopenia, Cachexia, and Wasting
Disease. </span></span><span style='font-size:10.0pt;line-height:150%;
color:black'>Nutritional recommendations for the management of sarcopenia. J Am
Med Dir Assoc. 2010;<span class=GramE>11:391</span>-6. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
class=GramE><span style='font-size:10.0pt;line-height:200%;color:black'>Cederholm
T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista
G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L,
Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE,
Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE,
Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van
Gossum A, Compher C; GLIM Core Leadership Committee; GLIM Working Group. </span></span><span
style='font-size:10.0pt;line-height:200%;color:black'>GLIM criteria for the
diagnosis of malnutrition - A consensus report from the <span class=GramE>global</span>
clinical nutrition community. Clin Nutr. 2018; pii: S0261-5614(18)31344-X. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:200%;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%'>Yaþlýlýkta
Endokrinolojik Hastalýklarýn Tedavi Kýlavuzu, Türkiye Endokrinoloji Ve
Metabolizma Derneði, 2018 ISBN: 978-605-4011-29-2 1. Baský: Mayýs 2018<o:p></o:p></span></p>

</div>

</body>

</html>
